w ho annual report innovation dna work discipline geography drive scientific discovery redefine possible improve patient live work understanding disease world leader vitro diagnostic differ molecular level business track record allow build last develop new test medicine prevent meaningful partnership world diagnose treat disease bring research academia public healthcare institution patient need combined strength diagnostic pharmaceutical found family continue hold majority p e n n n v n p r n e r personalise healthcare strategy aim fit voting stake company stability allows recently launch new grant breakthrough partner right treatment right patient tradition sustainable thinking learn cancer treatment therapy designation great stride overcome setback focus last value patient cancer immunotherapy medicine food drug administration barrier healthcare develop world large biotech company develop society remain dedicated high tecentriq give new hope medicine add local access plan fully breakthrough medicine improve standard standard quality safety integrity legacy people specific type key diagnostic instrument integrate local business care oncology immunology infectious base respect individual bladder lung cancer test rich portfolio plan disease ophthalmology neuroscience community world live inroche global presence highlight redefine treatment oncology transform laboratory work employee worldwide basel kaiseraugst switzerland cancer immunotherapy tecentriq available cobas e platform launch fast simple mannheim penzberg germany bladder lung cancer laboratory testing read read north america europe employee employee recognise innovation manage rare blood disorder breakthrough therapy designation grant potential new medicine emicizumab significantly reduce food drug administration number bleed group people haemophilia read read chugai tokyo japan partnering improve care contribute sustainability formal agreement sign subsaharan roche rank sustainable healthcare company hanghai country improve access healthcare dow jones sustainability indices eighth year run china genentech san francisco read read usa asia key figure employee latin america employee chf million chf million africa australianew zealand employee employee group sale research development investment chf patient research development site manufacture site dividend participate clinical trial pharmaceutical diagnostic worldwide pharmaceutical diagnostic worldwide million patient roche medicine roche group headquarters large site base number employee treat medicine list essential medicine research development site pharmaceutical diagnostic manufacturing site pharmaceutical diagnostic sale site pharmaceutical diagnostic number employee express fulltime equivalent growth rate report constant exchange rate cer average content overview strategy market environment chairman shareholder letter ceo shareholder letter business performance group performance pharmaceutical performance diagnostic performance science innovation forefront find cure cancer progress pipeline access healthcare complex challenge focus partnership progress africa people develop leader attract retain good talent safety health environment ensure occupational health safety minimise ecological footprint community engagement provide longterm disaster relief invest education integrity business patient safety come matter engagement corporate governance board director corporate executive committee remuneration report principle remuneration component roche reporting approach report approach roche reporting approach commit transparent reporting endeavour materiality accordance gri g guideline drive economic social environmental performance material topic conduct materiality analysis corporate materiality level gather input feedback rochecom diligence financial performance internal external source conference drug efficacy safety counterfeiting materiality regular interview oneonone discussion biosimilar safety roche expert key stakeholder disease awareness treatment education key performance enable include topic stakeholder patient organisation support indicator report scope boundary consolidate group risk report cover group consider important business product portfolio strategy rochecom provide integrated information financial material risk discuss annually healthcare sector patient organisation patent policy performance online annual nonfinancial performance annual report corporate executive committee review employee medium investor payer regulator datum transparency clinical trial report finance report online report audit committee board director government rd pipeline strategy personalise rochecomar cover region division january board directors effectiveness healthcare december risk management process regularly monitor final step combine insight sustainable healthcare roche annual group risk advisory team overall identify material topic stand highly growth strategy emerge report pdf reporting scope define outlined process review externally appropriate relevant key stakeholder develop market rochecomarepdf finance report significant significant impact longterm success pricing change scope compare risk management embed level employee engagement talent retention roche finance group pharmaceutical diagnostic material topic reflect business executive compensation report pdf reporting accordance late gri division global function conduct formal priority report content highlight compensationbenefit rochecomfbepdf guideline risk assessment process year begin chapter aspect leadership commitment follow gri g guideline develop risk plan material risk boundary accord gri organisational effectiveness gri g index global reporting initiative disclosure core group risk advisory facilitate risk discussion compliance rochecomgriindex application level report number additional support business specialist area build concrete action relate topic environmental responsibility indicator requirement core level digital medium security compliance operational activity measure performance occupational accident risk management list online gri g index sustainability training session platform define indicator process community engagement rochecomrisk establish help employee manage result materiality analysis endorse supply chain management management risk management monitor mitigate risk appropriately roche corporate sustainability committee risk management policy set approach chief executive officer identify managing report internal read corporate governance external risk opportunity identify strategy business sustainability risk opportunitie external assurance annual basis integrate exist current annual report include independent risk management process assurance report nonfinancial reporting prepare pricewaterhousecoopers ag independent assurance report roche sdgs sdgs roche increase access healthcare support community aim person need medicine support programme result last improvement diagnostic test able access benefit sustainable benefit community operate hiv global access programme partnering start partnership maharishi institute international organisation offer sustainable solution hiv viral south africa cover university education cost student load test eligible low middleincome country date futurelab genentech science education programme develop seven million infant test partnership south san francisco unify school district sign memorandum understand country support science education elementary school high school subsaharan africa help patient well access healthcare contribution sustainability read access healthcare chapter read community engagement chapter commit sustainability year contribute number united nations sustainable foster diversity inclusion meet high standard business ethic development goal strive create work environment include facet know integrity foundation business diversity license operate key ability lasting impact public health pioneer programme provide opportunity highpotential september united nations general forefront develop effective woman systematically acquire sponsorship valuable feedback roche support respect human right implement human right assembly unanimously adopt sustainable therapy diagnostic tool diagnose treat career progression protect respect remedy approach un human rights rochecom contribution development goal sdgs end poverty protect monitor cancer neurological disorder support international assignment council ruggie framework humanright un sdgs planet ensure prosperity assignment develop region employee complete mandatory training ensure understand rochecomunsdgs sustainable development agenda objective sdg achieve universal health group code conduct include voice compliance agreement mark important milestone coverage prerequisite achieve well concern business practice behaviour phase sustainable development access safe effective highquality medicine engagement wide range stakeholder diagnostic test develop innovative read people chapter read integrity business chapter approach collaboration international committed support sdgs line local player strive break access business strategy particular sdg aim barrier patient world ensure healthy life promote wellbee support universal healthcare coverage goal communicable disease tuberculosis malaria noncommunicable disease include list select example cancer mental disorder universally contribution number sdgs minimise environmental footprint recognise area high unmet medical need aim minimise ecological footprint increase use renewable resource continue expand global business goal reduce energy consumption compare level plan increase proportion sustainable energy compare level read safety health environment chapter roche strategy strategy roche strateg focus find new medicine diagnostic help patient live long well life evolve practice medicine focus people fitting treatment patient make mark guide purpose molecular biology seamless integration patient need company year pharmaceutical diagnostic capabilitie history advance field medicine diversity approach maximise innovation bring novel treatment diagnostic patient longterm orientation patient remain core reason come work day delivery create value stakeholder distinctiveness decisionmake partner choice bring significant medical excellence science accountable transparent benefit patient doctor payer offer great place work employee sustainable impact society create topquartile total focus fitting treatment patient shareholder return investor provide right therapy right group people right time inhouse delivery structure combination pharmaceutical diagnostic value stakeholder build innovation uniquely position deliver personalise healthcare develop internal end take people integrity courage capability build strategic partnership passion difference patient ready stage personalise healthcare people proud roche combine insight multiple datum source embrace diversity culture people sophisticated analytic drive effective group inclusive encourage efficient research allow well decision richness idea approach bring patient decisionmake principle process continue concentrate energy emphasise transparent dialogue clear accountability entirely prescription medicine vitro encourage high degree empowerment diagnostic diversify sector like generic overthecounter medicine structure build innovation autonomous medical device research development centre alliance external partner foster diversity agility pursuit excellence science global geographical scale reach enable distinctiveness rest key element bring diagnostic medicine quickly people exceptionally broad deep understanding need roche market environment market environment roche rapidly change market environment tablettoward digitisation life expectancy increase new medicine market time globally yearsthe fast increase continue invest future yield healthcare quality improve breakthrough therapy designation btds year heart attack kill seven million people quick accurate diagnosis difference life death slowly cope age population grant fda medicine grow number patient chronic establish btd accelerate disease light demographic change development review medicine lead healthcare company decisive demonstrate substantial improvement exist preventive care gain importance testing option stage treatment contribution higherquality diagnosis therapy achievement testify high lead increase focus diagnosis monitor laboratory system generate wealth datum allow treatment breakthrough biology technology level innovation pursue research prevention technological advance drive physician provide patient holistic accurate opening new way improve save patient development activity opportunity connect different instrument precise diagnose prevention live healthcare budget increase genentech chugai external alliance platform hospital example need able treatment solutionsall fast pace pressure change healthcare landscape offer reflect broad range approach science connect device healthcare solution untold opportunity researchfocuse healthcare centralise monitoring realtime datum analysis address need policymaker company extensive knowhow environment change rapidly new regulator challenge opportunity arise diversity roche positioned capitalise technological debate access healthcare pricing regional gain average life expectancy year approach idea agility help progress diagnostic pharmaceutical reimbursement gain momentum policy turn opportunitie success roof enable leverage molecular discussion world arrival highly year biology expertise future integrate effective hepatitis c medicine steady stream gain knowledge datum management realworld datum create insight target cancer medicine raise concern scientific medical expertise critical datum research development purpose affordability payer increasingly claim identify effective treatment option modern support well treatment decision patient funding challenge induce expensive innovative molecular diagnostic tool help guide care rationale drive collaboration medicine soon insurmountable appropriate therapy identify specific drug foundation medicine flatiron health enable target body offer prospect well leverage datum advanced analytic government respond challenge personalise healthcare digital revolution improve development medicine way country example africa america southeast asia europe potential transform healthcare therapy decision patient care guideline approval biosimilar outcome data clinical practice adopt discussion addition source oecd health glance increasingly digitise analysed addition late advance diagnostic technology grow number health technology region define world health organization exist data set derive clinical trial work develop laboratory different assessment agency world assess development enable small patient group instrument platform connect evidence clinical effectiveness safety translate knowhow number relate specific therapy outcome single system enable vast set costeffectiveness medicine test significant benefit patient result effective treatment approach healthcare system recently bring world health statistic monitor health sdgs rochecomvalueofinnovationstep frost sullivan healthcare medical device connectivity interoperability roche market environment market environment roche remain key growth driver appreciate payer ask evidence number facility help reduce operational outperform market growth patent cliff effectiveness new medicine complexity cost maintain compliance pharma market growth pharmaceutical industry effectively manage potential budgetary impact order effectively meet increase demand treatment try address product deliver strong pipeline need riskshare agreement address innovative new medicine expand need payer aim help patient gain access global biologic manufacturing network building maintain trust stakeholder late treatment option quickly time low capacity utilisation pharma industry face challenge earn realign small molecule network reflect trust particularly government regulator improve productivity change portfolio society large address challenge company late figure rd productivity suggest strengthen culture ethic integrity decline late level approval new molecule past year adopt high governance standard improve largely stream promise relationship employee shareholder new molecule approve year recent developmentssuch new technology stakeholder well understand biology disease significant increase datum human health world north america europe asia pacific year ago company operate isolation development lead scientific breakthrough source im midas achieve great deal previously intractable area immuno future collaboration stakeholder oncology cardiovascular disease hepatitis c diagnostic business china fact key industry remain critical concern remain return growth driver shift business opportunity success early research deliver drug development emerge market mature product increase collaboration market experience slow growth internal external stakeholder key way increase productivity find new way harness scientific technological advance perform expensive clinical study decadesold key sustained growth pharmaceutical improve rd productivity deliver pricing approach phase ii iii clinical trial source cder nme bla filing approval fda website diagnostic alike people access new access solution adapt evolve give way cuttingedge study design change medicine test develop broad set regulatory environment pace drug development effectively sustain economic growth initiative improve patient access allow evaluation promising compound remain key growth driver world include work government recognition commitment specific patient population force set pharmaceutical industry despite recent slowdown disease awareness campaign train lab technician environment society roche name group right priority shift resource product market benefit structural characteristic sophisticated diagnostic training community leader sustainability pharmaceutical impact patient life strive accelerate approval pathway large healthcare worker provide flexible pricing biotechnology life science industry dow agile decisionmake roche team grow population stable highquality solution support payer reimbursement decision jones sustainability indice djsi eighth come look promise molecule infrastructure consecutive year different research organisation assess good way fast advance medicine key emerge market record low level development process ultimately patient growth expect grow steadily benefit soon china grow population access innovative medicine sustain market growth comes improve efficiency notwithstanding geopolitical risk assume consider rd productivity continue access expansion refine manufacture network optimal bcg perspective onbcgcombiopharmardprod roche overview overview roche hon senator dr beth mugo kenya tackle problem long go politic fight kenya successful reduce toll economic social political right communicable disease aid tuberculosis disadvantaged kenya especially woman malaria recent year seen elect female member parliament noncommunicable disease cancer nairobi represent constituency major killer personal story heighten year senator awareness suffering cause cancer need action party election join government assistant minister education publicprivate partnership essential address serve minister public health healthcare issue complexity scope sanitation priority kenya roche contribute share extensive improve maternal health establish knowledge oncology help improve patient health centre country training access timely diagnosis treatment nurse able significantly reduce death rate woman give birth child need come tackle disease current lady kenya take establish beth mugo cancer progress maternal care foundation promote access information detection zero campaign treatment breast cervical prostate cancer roche partner provide learn breast cancer research datum basic training cancer support shock instinct secret patient organisation link likeminde stigma associate disease international organisation kenya lucky tumour early stage treated successfully take base kind strong partnership courage decide come forward story envision country healthcare accessible importance early detection generate affordable people inform great deal medium coverage follow upsurge health matter health sector woman country get checkup serve public efficiently recalibrate healthcare priority fight cancer work united nations development partner nongovernment organisation roche chairman shareholder letter chairman shareholder letter roche shaping future focus innovative test medicine enable play key role overcome challenge face global healthcare dear shareholder year decode human challenge face global health remain immense genome adoption united nations instance increase chronic disease millennium health goal opportunity emergence new epidemic spread antibiotic challenge global healthcare great resistance way achieve endure solution confident roche strength adopt integrate perspective engage pharmaceutical diagnostic place international multistakeholder collaboration actively help shape advance healthcare roche ready commit innovation tomorrow united nations sustainable development goal health spur fact primarily strong core business roche rank sustainable healthcare volatile environment impact company dow jones sustainability indices austerity measure succeed increase eighth year run develop novel product remain way sale billion swiss franc address difficulttotreat disease remain net income come billion franc great contribution society way particularly proud product launch create value consequently invest approximately new treatment available fifth sale research development type cancer improve automate translate billion swiss franc create value vitro diagnostic dr christoph franz chairman board growth rate report constant exchange rate cer average roche chairman shareholder letter chairman shareholder letter roche light good fullyear result new medical technology digitisation create technological possibility global pressure imcore network partnership huge opportunity enormous scientific healthcare system far foundation medicine flatiron health propose increase dividend chairmans video technological advance development novel product project kenya examplesalbeit rochecom world major life science technology centre future vital treatment test pivotal onesof wideranging activity th consecutive year archair pioneer spirit wealth idea available patient need today external partner demonstrate way truly compelling regrettably variety reason access approach opportunity challengeswith guarantee openness team spirit tenacity roche site shape future mean continue partner november instance set major task establish maintain look forward welcome th annual develop product offering market globally imcore network academic institution function healthcare system course general meeting roche holding ltd march entrepreneurial spirit sound strategic work roche advance research cancer responsibility individual state great light company good fullyear result instinct thank group immunotherapy diagnostic play country late medicine diagnostic product board director propose dividend employee dedication crucial role search treatment tailor available increase swiss franc share nonvoting external partner willingness work patient individual immunobiology rudimentary healthcare resource lack equity security subject approval roche share goal patient wellbee autumn travel subsaharan th consecutive dividend increase aim integrate diagnosis treatment countrieskenya nigeria cte divoire despite digital technology application great frequent absence basic necessity place like draw attention change like thank shareholder extent clinical picture treatment option include clean water infrastructure knowhow roche board director professor pius baschera confidence numerous diverse chronic illness roche team field decide stand reelection way provide doctor patient work passionately local partner provide annual general meeting follow year tenure comprehensive information aid decisionmake treatment patient behalf board director like process partnership enter extend sincere thank valuable foundation medicine flatiron health certain achieve great deal contribution roche success access datum promise analysis tool collaboration government patient group field cancer roche develop aid organisation show instance delight able propose anita hauser pioneering solution integrate interpret progress kenya new oncology centre successful swiss business leader new member diagnostic datum wide variety source set agreement board director vicechairwoman government training healthcare specialist board director globally operate family enable modern diagnostic test cofunde business bucher industry ag anita hauser dr christoph franz develop pioneering solution free breast cancer treatment patient public strong entrepreneurial background chairman board institution region country interpret diagnostic datum endeavouring promote access healthcare mean tailor local solution source roche board director board director roche board director leave right prof dr richard p lifton c e andr hoffmann vicechairman paul bulcke b e corporate governance sustainability committee representative shareholder group pool b audit committee julie brown b e voting right c e peter r voser c e c remuneration committee presidiumnomination committee prof sir john irving bell b e dr andreas oeri representative dr severin schwan f e nonexecutive director shareholder group pool voting right e f executive director bernard poussot c e prof dr pius baschera e committee chairperson dr claudia sssmuth dyckerhoff b e roche board director december dr christoph franz chairman c e roche ceo shareholder letter ceo shareholder letter roche achieve medical breakthrough see important advance include regulatory approval cancer immunotherapy medicine file new treatment multiple sclerosis improve patient livesthis ambition dear shareholder achieve financial target drug administration pharmaceutical sale diagnostic sale speed approval process increase market growth roche business success reflect diagnostic division introduce number core earning share nonvoting equity key new instrument test particular product security increase like mention new immunochemistry platform cobas e new module clinical laboratory important future product carry immunological test hour pipeline good advance enable doctor fast extremely reliable short period launch new medicine treatment decision pipeline treat aggressive cancersskin cancer cotellic lung cancer alecensa tecentriq leukaemia venclexta complex highly innovative product bladder cancer tecentriq therapeutic develop people different discipline area file marketing application business area work closely extend eu new medicine multiple sclerosis sincere thank employee good advance ocrelizumab achieve positive latestage clinical outstanding achievement trial result new molecule emicizumab treat haemophilia bloodclotte disorder harness scientific excellence improve patient additionally medicine grant life possible help live long breakthrough therapy designation food goal drive day day roche dr severin schwan chief executive officer growth rate report constant exchange rate cer average roche ceo shareholder letter ceo shareholder letter roche fight cancer late advance treatment multiple forefront cancer immunotherapy work closely payer service provider sclerosis ms highly encouraging ms investigational candidate currently introduce flexible pricing solution immunotherapeutic approach ceos video autoimmune disorder immune system clinical development phase european countriesinclude different rochecomarceo attack body datum largescale trial immunotherapeutic medicine tecentriq approve price medicine combination therapy combination therapy prove show potential new medicine ocrelizumab treatment bladder lung cancer versus monotherapie breast skin cancer highly effective somewhat rare represent major improvement bladder country initiate pilot project promise form progressively deteriorate disease cancer treatment option year medicine collaborate set necessary treatment find date appreciably extend life expectancy people infrastructure andfor example uswe advancedstage lung cancer actively engage discussion payer new world leader oncology strive advance pricing model constant exchange rate plan new approach well treat cancer cancer fact people respond differently medicine increase dividend swiss franc cell resourceful look way circumvent remain huge medical challenge overall work government payer treatment point time begin immune system extremely complex aim goal ensure degree patient benefit roche strongly position future multiply late immunotherapeutic cancer check effectively long innovation product take account world large biotech company leader approach prove promise termor defeat itby highly promising cancer therapy equip good help bodys immune system combination complementary preparation expect witness market launch product pipeline industry number recognise fight cancer effectively example immunotherapeutic agent biosimilar important laboratory diagnostic confident roche time reason hope chemotherapy target antibodie medicine confident able continue year success story able cure patient advanced cancer tooor currently test combination meet challenge continually improve transform cancer chronic disease roche clinical trial standard care base strength develop combination therapy prove new compound view novel treatment newly launch medicine harness scientific excellence approach strive flexible pricing important development business model instead establish practice pricing current year expect number key clinical improve patient live possible medicine base vial miligramme want study result product approval overall link remuneration closely patient benefit anticipate sale grow low midsingle digit help live long goal instance vary medicine constant exchange rate aim core dr severin schwan depend indication earning share grow broadly line sale chief executive officer drive day day roche combination roche corporate executive committee corporate executive committee roche corporate executive committee leave right daniel oday dr stephan feldhaus dr sophie kornowskibonnet osamu nagayama ceo roche pharmaceutical head group communication head roche partnering chairman ceo chugai roland diggelmann dr gottlieb keller dr alan hippe dr michael varney ceo roche diagnostic general counsel chief financial officer head genentech research early development gre cristina wilbur dr severin schwan prof dr john c reed head group human resource ceo roche group head roche pharma research early development member enlarge corporate executive committee pre roche corporate executive committee december roche business performance business performance roche bu sine pe r mance recently launch new medicine strengthen lead position laboratory business time invest product pipeline material topic cover chapter investor rd industry product portfolio strategy growth strategy emerge develop market provide medicine diagnostic instrument different test patient laboratorie healthcare professional roche business performance business performance roche g latin america sale advance sale growth alecensa significantly reduce risk disease japan lead centralised worsen death compare crizotinib current point care solution business standard care people alkpositive nsclc gazyvagazyvaro show positive result high number launch pharmaceutical major clinical trial gallium follicular lymphoma ood performance division roche recently launch new medicine cotellic separate trial goya medicine diffuse large advanced melanoma alecensa lung cancer venclexta bcell lymphoma reach primary study goal chronic lymphocytic leukemia jointly commercialise abbvie tecentriq bladder lung cancer broaden diagnostic portfolio group sale rise chf billion despite perjeta actemraroactemra mabthera rituxan addition fda breakthrough therapy designation roche add key instrument high investment launch new product japan sale grow despite biennial price grant roche medicine major test comprehensive portfolio new product development core eps grow fast sale cut special price reduction rule bestselle highlight launch roche cancer instrument cobas e immunoassay module core ep growth reflect good underlie medicine tamiflu alecensa actemraroactemra immunotherapy medicine tecentriq coaguchek inrange system monitor vitamin k business performance impact change key sale contributor international region fdaapprove treatment people specific type antagonist therapy accuchek guide group swiss pension plan ifrs net income sale gain drive asiapacific latin bladder cancer year furthermore generation blood glucose monitoring system constant exchange rate swiss francs america subregion fda clear tecentriq use previously treat metastatic nonsmall cell lung cancer nsclc fda approve accompany diagnostic sale pharmaceutical division rise diagnostic divisional sale increase pivotal oak trial show people form ventana pdl sp test complementary chf billion drive growth perjeta herceptin chf billionabove market growth centralise lung cancer receive tecentriq live significantly diagnostic determine pdl status patient actemraroactemra partially offset low point care solution main contributor long regardless pdl status compare bladder lung cancer cobas egfr sale pegasys tarceva lucentis lead immunodiagnostic business receive chemotherapy additional data mutation test v companion diagnostic lung present ectrim congress september cancer medicine tarceva fda grant pharmaceutical sale advance lead emea north america show roches ocrelizumab increase disease premarket clearance clia waiver respiratory medicine xolair esbriet region division large market sale control relapse primary progressive cobas liat influenza ab rsv test recently launch medicine tecentriq alecensa increase lead centralised point care multiple sclerosis rm ppm roche seek pointofcare test extend molecular testing contribute growth sale eye drug solution sale growth north america partially regulatory approval medicine rm liat system influenza ab streptococcus lucentis cancer medicine avastin tarceva offset decline diabetes care business ppm eu fdas action date include respiratory syncytial virus rsv fda decline grow use therapeutic face continue pricing pressure sale increase decision march approve roche test detection zika virus option europe sale growth drive asiapacific mainly drive china roche present important clinical result outlook pivotal study group people roche expect sale grow low midsingle key figure haemophilia show prophylaxis digit constant exchange rate core earning emicizumab lead significant reduction share target grow broadly line sale chf millions chf million change change cer chf number bleed time phase iii study constant exchange rate roche expect group sale chugai jalex find firstline treatment increase dividend swiss franc pharmaceutical division diagnostic division core operating profit core ep diluted chf ifrs net income growth rate report constant exchange rate cer average ifrs international financial reporting standard roche professional diagnostic europe middle east africa clia clinical laboratory improvement amendment european committee treatment research multiple sclerosis roche business performance business performance roche ale pharmaceutical division increase especially china follow approval lung increase use people moderate progressive cancer indication sale disease roche stepping effort chf billion drive growth breast cancer avastin broadly approve market improve disease awareness inform indication decline largely grow patient caregiver need early medicine actemraroactemra use new immunotherapy agent lung sustain treatment ipf cancer setting actemraroactemra rheumatoid arthritis herceptin perjeta kadcyla combine mabtherarituxan common form gazyvagazyvaro chronic lymphocytic form juvenile idiopathic arthritis increase herpositive breast cancer herpositive blood cancer rheumatoid arthritis certain leukaemia cll rituximabrefractory follicular use actemraroactemra single agent metastatic gastric cancer herceptin herceptin type vasculitis sale continue rise despite lymphoma sale expand europe despite subcutaneous formulation remain key growth sale help additional reimbursement competitive pressure increase demand mainly increase competition cll gazyvagazyvaro driver globally approval china continue growth see china europe growth china approve cll country long duration treatment combination support expand regional access largely follow eu approval medicine recently launch medicine perjeta perjeta sale advance particularly diffuse large bcell lymphoma previously treat follicular lymphoma alecensa people alkpositive advanced strongly europe medicine half early uptake indication nsclc good uptake sale approve use surgery early breast avastin advance colorectal breast lung encourage growth remain strong japan follow fda pharmaceutical cancer kadcyla sale fuel increase kidney cervical ovarian cancer relapse approval tecentriq bladder lung cancer rochecom demand international region mainly glioblastoma type brain tumour sale continue esbriet idiopathic pulmonary fibrosis market uptake strong pharmaceutical expand access grow strongly international region ipf sale continue expand topselle pharma product chf millions mabtherarituxan avastin herceptin perjeta actemraroactemra xolair lucentis activasetnkase tarceva kadcyla oncology immunology oncology oncology oncology immunology immunology ophthalmology cardiovascular oncology oncology growth rate report constant exchange rate cer average roche business performance business performance roche europe eastern europe middle east africa eemea japan regional performance good growth region europe latin america latam asiapacific apac market continue area significant european market healthcare largely opportunity despite increase complexity drive publicly fund continued face increase demand rise competitive pressure dynamic regulatory strained healthcare system despite european environment advance technology shift medicine agencys centralise approval medicine valuebase healthcare model navigate time european authorisation eemea latam apac canada form international region challenge remain focused deliver reimbursement continue vary country differentiate product work government spending level healthcare stakeholder healthcare community create significant disparity access medicine differentiate product support physician choice eu commitment accelerate ensure patient access medicine widen patient access medicine europe international expand access medicine enable develop new pricing solution healthcare latam region experience consistently achieve reimbursement province china fda follow specific approval procedure system flexibility make reimbursement high growth recent year result increase cover million people apac region medicine create programme decision europe region contribute healthcare spend government attention contribute overall pharmaceutical business expedite approval promise new treatment overall pharmaceutical business deliver programme improve access healthcare despite growth drive herceptin mabthera intend unmet medical need growth drive perjeta actemraroactemra investment significant challenge remain rituxan avastin breakthrough therapy designation btd programme mabtherarituxan germany france italy include lack infrastructure train receive btds indication large contributor sale professional low level education awareness despite inherent volatility multiple barrier mean award total btds disparity local private public quality healthcare significant opportunity fda establish programme japan healthcare system different latam growth development eemea region universal healthcare insurance system country address issue roche collaborate drive access medicine aim implement fuelled strong sale new exist japan face significant pressure reduce overall partner help strengthen national tailor solution middle east market medicine record yearoveryear medical cost addition general drug health plan increase access test work stakeholder adapt regulation growth account total price revision occur year special medicine latam contribute overall local approval base regulatory submission pharma business half total sale marketexpansion reprice rule newly introduce pharmaceutical business grow drive market help accelerate product attribute oncology medicine drive apply avastin give patient avastin herceptin perjeta sale growth registration timeline make innovative recent approval tecentriq bladder receive adequate testing treatment chugai drive inflationary price increase medicine available early patient fda btds lung cancer alecensa lung cancer make effort disseminate information argentina example patient emerge market benefit focrorg prepare potential fda approval healthcare delivery different disease area innovative medicine product breakthrough medicine outside oncology include country chugai contribute overall challenging year apac region contribute regional growth avastin perjeta therapy ocrelizumab ms pharmaceutical business sale increase macroeconomic slowdown key kadcyla overall eemea market contribute drive tamiflu alecensa actemraroactemra market china taiwan focus pharmaceutical business grow roche business performance business performance roche type multiple sclerosis ms disability disability disability time time time strong heritage relapse ms secondary progressive ms relapse primary progressive ms secondary progressive ms relapse progress oncology neuroscience people ms initially diagnose relapse ms rm time majority people rm progress secondary progressive ms source multiple sclerosis international federationtrojano et al transition relapsingremitte ms irreversible disability clinical evaluation neurol sci forefront find cure cancer launch new cancer medicine significantly year roche forefront improve patient outcome tecentriq bladder lung develop medical solution fight cancer cancer venclexta chronic lymphocytic leukaemia turn multiple sclerosis common form disease fu synthesise roche anticancer alecensa lung cancer cotellic skin cancer central nervous system cns research long characterise clearly define relapse drug inhibit cell growth roche history roche world commercially include neurologic symptom prevalent biotech product roferona approve major highlight launch available benzodiazepine medicine librium highly disable form disease primary treatment previously fatal form blood cancer cancer immunotherapy medicine tecentriq valium invent roche scientist progressive ms ppm display steadily worsen cancer immunotherapy revolutionise way leo sternbach roche introduction symptom onset unlike rm year roche bring new cancer treat proud product major milestone impact approve treatment ppm medicine cancer patient longterm durable leader field expect important data medicine feel today remission cure possible specific investigational cancer immunotherapy research advance lead increase disease setting example herceptin show molecule monotherapy combination year later reach turn development new efficacious treatment reduce number case metastatic approach end point understand brain nervous high efficacy treatment typically positive breast cancer early set system lead tremendous opportunity accompany high safety risk people aggressive form lymphoma gain regulatory approval medicine continue invest broad research development reason physicians patient cautious mabtherarituxan chemotherapy mean patient need able receive programme focus disease area highefficacy treatment show cure disease majority treatment immediately reimbursement negotiation patient type healthcare infrastructure contribute psychiatric disorder include schizophrenia need highefficacy medicine offer cancer significant progress need delay number year patient access depression favourable safety profile currently seek overcome challenge disease innovative new medicine case neurodevelopmental disorder include autism regulatory approval ocrelizumab ms oncology prove late spectrum disorder down syndrome fragile x treatment rms ppms ppms rochecom goal forefront find cure neurodegenerative disorder include parkinson treatment type oncology cancer demonstrate fact recently make effort accelerate access disease alzheimer disease disease pivotal rms trial medicine medicine world example neuroinflammatory disorder include show high efficacy versus rebif interferon betaa personalise reimbursement model neuromyelitis optica multiple sclerosis ms twoyear period ocrelizumab demonstrate framework enable flexible pricing solution favourable safety profile phase iii study key achievement oncology allow medicine price accord ms particular significant advance datum suggest ocrelizumab potentially benefit deliver different indication achieve fight disable disease early treatment pathway neuroscience million cancer patient treat combination provide flexibility past year numerous administer twiceyearly infusion offer people rochecom new cancer medicine recently introduce come reimbursement decision ensure timely treatment option available relapse ms rms ms frequent dose schedule neuroscience fda breakthrough therapy designation grant cancer access innovative medicine patient medicine weisgerberkriegl u et al estimation epidemiological effect trastuzumab year european countries j clin oncol sehn l gascoyne r diffuse large bcell lymphoma optimize outcome context clinical biologic heterogeneity blood hauser sl et al ocrelizumab versus interferon betaa relapse multiple sclerosis nejm online roche business performance business performance roche north america europe middle east africa emea japan ale diagnostic division grow strongly chf billion region report sale growth latin america asiapacific centralised point care solution business grew support tender win large contributor division sale country performance integrate serum work area solution comprise immunodiagnostic tissue diagnostic sale increase sale division sale growth drive asiapacific region clinical chemistry segment advance stain portfolio primary main driver strong growth stain respectively companion diagnostic sale show continue molecular diagnostic include sequence strong growth region contribute growth north america strong abovemarket growth sale increase virology portfolio increase access healthcare diagnostic performance drive laboratory business diagnosis monitor hepatitis hiv diabetes care sale decrease predominantly solution demographic shift advance roche continue gain market share sale hpv human papillomavirus continued price pressure science technology lead globally grow laboratory decentralise coagulation monitor screen sale advance blood screening volume test leader field vitro segment important new business diagnostic roche position benefit recently launch product diabetes care development public funding challenge market condition continue impact constraint lead consolidation laboratory region overall performance topselle product portfolio chf million hospital number people diabete continue grow awareness asiapacific region major driver condition need manage adequate division growth immunochemistry key blood glucose monitoring system contributor china generate absolute sale growth market sale increase emea region drive region continue volume growth core laboratory business contribution market expand access testing diabetes care sale vary different level market maturity stable economic development africa major healthcare access programme implement number latin america business segment contribute cobas cobas cobas ventana accuchek local government close collaboration growth sale expand diabete care immunodiagnostic clinical chemistry virology advanced staining diabetes care international organisation unaid partner industry roche support sale growth japan drive centralised initiative sustainable commercial offer point care solution tissue diagnostic overall diabete care sale decline business diabete care decline region growth see market roche professional diagnostic growth rate report constant exchange rate cer average roche business performance business performance roche modern diagnosticsfaster simple result accurate connect lab histopathology laboratory provide work increase efficiency exceptional stain quality connectivity laboratory solution want modern connect lab provide interconnect instrument incomparable breadth menu allow fast result innovation support healthcare professional new cobas integrate haematology analyser help good patient decision launch country accept ce mark fast efficient way fully connect compare current method innovative laboratory automate processing integrate automate system offer streamlined solution broaden rich test menu streptococcus include respiratory syncytial workflow goal prepare stain analyse microscopy blood range new test vitro diagnosis virus rsv infection rsv cause slide automation digitisation reduce need approve clear regulatory authority acute low respiratory tract infection connect lab offer wide array test resourceintensive manual microscope reviews certify launch new test add infant year age essential increasingly able deliver require blood testing deliver highly comprehensive portfolio improve decision differential diagnosis rsv influenza result different testing discipline accurate result fast make healthcare support laboratory ensure appropriate treatment soon onset blood sample thank automate workflow effort increase operational efficiency symptom integrate solution customer benefit coaguchek inrange system fully interconnect instrument incomparable bluetoothenable ptinr home health device june fda approve cobas egfr mutation ventana pdl sp test approve breadth menu fast highly accurate result give patient healthcare provider great test v use plasma sample companion fda complementary diagnostic provide pdl control coagulation status ability diagnostic nonsmall cell lung cancer nsclc status patient metastatic urothelial cancer new member cobas modular monitor vitamin k antagonist therapy patient therapy tarceva fda approval consider treatment fdaapprove analyser series cobas e module selftesting coaguchek inrange set new liquid biopsy test aid clinical decision immunotherapy tecentriq fda approve immunodiagnostic represent major step forward standard care enable provider monitor make test fdaapprove companion test nsclc realise connected lab launch patient ptinr datum reduce visit lab diagnostic detection epidermal growth module design maximum consolidation factor receptor egfr gene dna derive new menu zika testing enable healthcare high throughput continuous operation accuchek guide nextgeneration blood plasma tumour tissue professional quickly diagnose infection simultaneously reduce waste glucose monitoring system launch virus help prevent unit blood generate new system double currently country design everyday august fda grant premarket clearance infected zika virus release blood available immunochemistry testing capacity blood glucose monitoring easier provide k clearance clia clinical laboratory transfusion patient puerto rico floor space require low sample advanced accuracy reliable diabetes management improvement amendment waiver cobas fda grant approval cobas zika assay volume deliver fast reliable consistent support people diabete reduce time influenza ab rsv test use cobas liat investigational new drug application protocol highly accurate patient result spend think daily therapy system pointofcare test extend issue emergency use authorisation routine simplify blood glucose monitor molecular testing influenza ab lightmix zika rrtpcr test fully automate system ventana improve test experience system primary staining improve workflow prothrombin time pt international normalise ratio inr assays evaluate extrinsic pathway coagulation piedimonte g et al respiratory syncytial virus infection bronchiolitis pediatr rev product available market roche business performance business performance roche cervical cancer screen diagnosis womens health screen manage diagnose identify woman risk identify woman require intervention identify woman treat secure health avoid disease cobas hpv test cintec plus cytology cintec histology product portfolio provide woman woman test positive genotype hpv important fertility marker assess ovarian health problem pregnancy hyperglycaemia physician additional insight critical health hpv high risk develop precancer reserve level elecsys amh test simple blood properly manage result birth issue allow informed decision cancer woman carry test perform day complication affect mother child precise step prevention early detection highrisk hpv genotype low risk menstrual cycle accuchek diabete management solution offer therapy stage woman life develop precancer cancer require accurate reliable blood glucose monitoring system followup test prevent unnecessary treatment preeclampsia pregnancy complication diabete management software solution education cancer example biomarker provide vital cost healthcare system cintec plus usually occur week pregnancy programme healthy diet moderate information tumour structural cellular cytology test address issue back landmark lead cause death complication exercise necessary insulin therapy tool genetic makeup subtype study palm test use mother unborn baby help blood glucose level healthy range physical characteristic tumour dualbiomarker technology simultaneously detect treatedthe cure delivery baby biomarker facilitate decisionmake guide specific biomarker p ki elecsys sfltpigf immunoassay ratio test predict portfolio comprise test identify infection therapy selection early intervention critical strong indicator presence transform rule shortterm risk develop microorganism include toxoplasmosis initial diagnosis breast cancer fiveyear hpv infection identify woman disease woman suspect preeclampsia syphilis cause treponema pallidum hepatitis b relative survival rate woman stage cancer benefit immediate intervention e parvovirus rubella cytomegalovirus herpe compare stage foetal genetic condition identify base simplex represent high risk cintec histology test support confirmation foetal dna circulation pregnant womans pregnancy newborn child early diagnosis cervical cancer screen diagnosis cervical disease actually present base blood harmony prenatal test new type initiation medical intervention critical cervical cancer preventable p biomarker guide pathologist screen test analysis fragment dna mother child form cancer thank implementation identification highgrade cervical disease tissue pregnant womans blood sample assess probability screen vaccination programme hpv biopsy miss standard morphologic genetic condition include trisomy maintain wellbee woman know cause cervical cancer interpretation test syndrome trisomy edward syndrome follow menopause disruption balance roche cervical cancer portfolio advance current recommend medical society trisomy patau syndrome test non bone breakdown new bone formation screen diagnostic approach medical diagnosis cervical disease global invasive highly accurate doctor cause woman lose bone fast rebuild value hpv screening establish globally standard care likely recommend invasive followup testing bone brittle easily break country start adopt hpvbase primary amniocentesis false positive result menu bone test provide early screening approach lead dramatic increase key information pregnancy complete assessment osteoporosis therapy efficacy screening effectiveness support datum average age firsttime mother rise gestational diabetes high blood glucose bone mineral densitometry test landmark athena clinical study cobas hpv fertility rate decline increase hyperglycaemia common diagnostic test currently fdaapprove hpv need information support family planning rochecom test use hpv primary screening woman natural conception artificial reproductive diagnostic age old technology antimllerian hormone amh parker js mullins cheang et al supervise risk predictor breast cancer base intrinsic subtype j clin oncol national institutes health seer statistical fact sheet globocan estimate cancer incidence fact sheet wright tc et al athena human papillomavirus study design method baseline result j obstet gynecol ikenberg h et al j natl cancer inst human papillomavirus hpv cervical cancer fact sheet zeisler h et al predictive value sfltplgf ratio woman suspect preeclampsia n engl j me roche business performance business performance roche dr thomas wright professor emeritus columbia university translate research clinical practice enter medical school planning fulltime translate clinical practice research quickly realise change fdaapproved procedure cervical pathologist combine research clinical cancer screening require clinical trial scale practice turn point career academic institution afford right moment partnership roche decide conduct ve love contact patient help athena trial patient understand emotional impact woman give opportunity participate work anxiously await result screen talented people roche design study cervical cancer importantly give protocol analyse clinical finding present clinical experience need help develop national result regulatory authority guideline manage treating disease fda approve roche hpv test year career standard screening primary screening sure pap test dramatically reduce number paradigm shift save life death cervical cancer develop country study show addition new screening technology half woman highgrade cervical physician effective cervical cancer cancer precursor pap test miss disease vaccine young woman target molecular therapy incredible think scientist discover hpv cause practically eliminate disease cervical cancer type decade country responsible case breakthrough open exciting new horizon term year collaboration roche prevention treatment detection patient impress knowledge dedication clinician people welcome input academic world treat trust partner trustful partnership academia industry partnership continue collaborate advance molecular screening technology follow roche evaluate biomarker play include roche diagnostic test reliably detect role cervical cancer add precision dna aggressive strain hpv detect treat disease early stage roche science innovation science innovation roche sc ie nce innovation material topic cover chapter product portfolio strategy rd pipeline strategy personalise healthcare scientist understand disease factor influence drug response critical late technology contribution un sdgs provide unprecedented insight scientist analyse discuss impact new drug candidate base digitise test result roche science innovation science innovation roche w e embrace good technology partnership leverage power unique pharmaceuticaldiagnostic structure advance science develop new therapy roche generate breakthrough insight turn todays science tomorrow cure develop product transform medical continue help define future medicine late researchsupporte technology leadingedge datum science allow unprecedented insight root cause disease parallel digitisation datum care people difficulttotreat deadly unprecedented opportunity match right enable expert discuss study result new drug candidate colleague globe real time disease build legacy embrace treatment right patient nonsmall cell lung good technology partnership leverage cancer nsclc instance consider power pharmaceuticaldiagnostic structure disease know dozen genetic alteration cause nsclc range medicine generation target medicine diagnostic forefront find cure cancer precise diagnostic test combination therapy available specifically target alteration patient answer hard question arise approval monoclonal antibodie mabthera allow million people instance hiv understand underlying personalised healthcare rituxan herceptin open door new infection live golden year likewise biology addition variation genetic paradigm mean clinical development cancer care landscape molecular herceptin manmade antibodie code study gene switch production patient daytoday live insight expand exponentially long ago approve late change treatment learn therapy cancer biopsy test single biomarker landscape herpositive breast cancer turning impact patient particular immune response research complex process capability screen blood tumour deadly disease eradicate difference way individual challenge lose sight fact tissue hundreds genetic alteration treat early stage metabolise medication increase granularity reason come work help patient parameter see mutation differ demonstrate exponential possibility drug build strong rd capability address medical need patient diagnose cancer new test cancer screen early diagnosis discovery development enable physician oncology immunology inflammation infectious individual patient tumour addition breakthrough therapy lead previously design treatment regimen personalise disease neuroscience ophthalmology remain know tumour development growth unimagined outcome cervical cancer patient need optimise efficacy safety open area include debilitate deadly intricately intertwine environment common cancer woman leading cause inherit genetic disease real tumour cell reside way immune cancer death worldwide good example advance science cancer immunotherapy difference patient child system respond cancer short tumour progress fight cancer today cervical cit roche launch imcore global network focus disease complex complex structure design evade natural cancer nearly avoidable thank vaccination lead cancer immunotherapy centre excellence continually raise bar rd project defence mechanism screen diagnosis treatment human goal imcore facilitate access new successful fact majority effort papillomavirus hpv infection primary cause technology emerge datum result viable drug study lead technology advantage roche offer lead portfolio test screen researcher world network approval benefit represent invest heavily novel tcell bispecific diagnosis hpv basic clinical scientist work learn opportunity bring close solve antibody tcb platform generating inhouse roche scientist goal develop potential mystery disease despite challenge engineer powerful anticancer antibodie design ophthalmology introduction lucentis cure people cancer continue invest heavily bold risk remain physically link immune cell cancer cell completely change space restore relentless pursuit innovative therapy part bispecific bind cancer cell improve vision patient destine blind roche invest chf billion research stateoftheart diagnostic transform patient live connect immune cell allow development rd year bring unaidsorgenresourcesfactsheet cdcgovcancerinternationalstatisticshtm iarc globocaniarcfroldfactsheetscancerscervixnewasp roche science innovation science innovation roche patient metastatic breast cancer immune cell attack innovative oak trial show significant improvement case inflame tumour immune cell call bispecific allow immediate scalable dose overall survival compare chemotherapy tlymphocyte find present survive month control approach harness immune system people recurrent nonsmall cell lung cancer tumour microenvironment goal use cancer suitable combination fail chemotherapy announce positive medicine checkpoint inhibitor eg tecentriq month therapie strategy explore multiple bispecific result pivotal phase iii gallium study investigational molecule antitigit format identify maximise clinical benefit anticd drug gazyvagazyvaro previously unleash tumour resident tcell attack kill patient anticeacd tcb rg untreated follicular lymphoma common cancer cell case immuneexclude tumour tcell bispecific develop roche enter form nhl study challenge tcell able recognise tumour invest powerful resource diagnostic clinical trial assess solid tumour go headtohead revolutionary able infiltrate tumour microenvironment clinical trial realworld datum work seamlessly different anticdcd bispecific different anticd drug mabtherarituxan achieve exert anticancer immune response scenario real time enhance organisation learn format rg rg study prolong disease control chronically relapse look combination tecentriq loop drive innovation laboratory treatment bcell malignancie non form lymphoma gazyvagazyvaro new target medicine avastin cotellic clinic ultimate goal hodgkin lymphoma nhl landmark provide hope clinical benefit investigational molecule antitgf revolutionise way personalise patient world drive tcell tumour cancer treatment provide subgroup patient type cancer cit rapidly improve therapy specifically design treat standard care despite year progress combination ambush tumour find immune desert cancer rich pipeline poised cancer remain devastating disease combination therapy new oncology tcell present aim redirect dramatic progress area million people diagnose cancer half century patient treat engage tcell use tcelldirecte decade addition clinical diagnostic million people die cancer mortality simultaneously different chemotherapeutic agent bispecific antibodie investigational technology expert develop industryleade rate fall cancer burden drug new precision drug rg personalise cancer vaccine platform use cuttingedge imaging science disease increase world ageing target combination treatment alternatively addition tcbs testing look inside tumour effect new drug population environmental factor launch multipronged attack molecular molecule cergutuzumab amunaleukin patient team digitise integrate remain committed sciencedriven research cause cancer viral disease teach rational ceailv fapilv rg interpret complex datum generate drive well unlock biological mechanism enable treat combination therapy need simultaneously tumourtargete antibody carry engineer decision drug development increase number cancer address drug resistance hit multiple mechanism virus use spread variant tcell growth factor interleukin il achieve longterm survival search resist treatment apply cancer antibodycytokine fusion protein stimulate extend expertise haematology potential cure recent research human immunology tumour proliferation tcell tumour learn nuance blood biology lead innovative approach treat study anticd monoclonal antibody rg cancer study million patient hit cancer hard cancer harnessing power immune system order prime andor activate tumour antigen pioneer science lead mabtherarituxan currently molecule exciting approach ability specific tcell provide help continue investigate venclexta breakthrough clinical development oncology clinical study understand good characterise know type need type immune cell call antigen therapy codevelope abbvie approve currently ongoing tecentriq human cancer primary immune presenting cell apcs antiox antibody fda early later year eu monotherapy combination therapy phenotype inflame tumour immuneexclude prime tumourfighting tcell start treatment patient chronic lymphocytic trial address diversity type cancer tumour immune desert phenotype journey attack cancer simultaneously leukaemia cll explore molecule include lung colon gastric ovarian breast kidney describe tcell immune system interact inhibit immunosuppressive cell call regulatory advance treatment blood cancer include bladder lung cancer claim live tumour classification system allow tcell treg finally molecule tcell bispecific antibodie anticdcd oral research day leading cause cancer death well determine appropriate treatment emactuzumab remove immunosuppressive small molecule activator tumour suppressor p development globally develop tecentriq combination combination strategy base individual cell tumour microenvironmentin idasanutlin antibodydrug conjugates polatuzumab rochecomresearch chemotherapy address need treatment immune biology ensure good chance case tumourassociate macrophage tam agents anddevelopment announce result tecentriq phase iii effective antitumour immune response example american association cancer research aacr cancer progress report clin cancer re slamon et al n engl j med swain et al n engl j me roche science innovation science innovation roche recently go blood cancer improve core social communication social novel compound pain target nav antibody develop collaboration chugai leverage insight blood cell biology haema interaction deficit potential yield nonopioid base mechanism treat pain enter phase complement system tology benefit patient nonmalignant blood treatment core symptom asd key innate immune defense mechanism study disorder active preclinical clinical programme digital biomarker derive datum generate potential enhance antibody underway haemophilia polycythaemia study latestage molecule crenezumab consumer device smartphone wearable broad range complementmediate disease vera paroxysmal nocturnal haemaglobinuria gantenerumab monoclonal antibodie potential increase precision clinical betathalassaemia haemophilia rare genetic different mode action design tackle decisionmake predict disease course asthma begin phase ii trial firstin disorder example unblinde phase iii study amyloid plaque build brain researcher develop suite smartphone class antibody inhibit bind interleukin show statistically significant reduction alzheimer disease patient unique assessment allow continuous monitoring st receptor pathway think number bleed time people treat expertise diagnostic develop new test assist symptom fluctuation number neurological involve variety lung ailment st emicizumab prophylaxis compare receive clinician diagnose alzheimer condition include parkinson disease ms antibody inlicense amgen potentially offer prophylactic treatment assessment complement conventional gamechange treatment patient severe psychiatric disorder test selective physicianle assessment limit asthma innovative multipronged study neuroscience inhibitor subtype gammabutryic acid availability expert centre resourceintensive explore biomarker associate asthma invention telescope open receptor cognitive impairment associate represent snapshot time chronic obstructive pulmonary disease copd previously mysterious universe advanced imaging schizophrenia randomise clinical trial technology allow unparalleled access begin earlystage clinical study novel immunology inflammation infectious disease promise candidate rich antiviral working human brain turn compound trace amineassociate receptor develop medicine area immune pipeline treatment hepatitis b virus hbv point understand biologic mechanism taar partial agonist pdea inhibitor mediate disease treat number illnesse infection include directacting antiviral underlie pathology nervous system disorder treatment negative symptom schizophrenia include rheumatoid arthritis ra systemic lupus immunomodulatory molecule consider strong pipeline industry early clinical study roche company erythematosus sjgren syndrome novel synergistic combination cornerstone roche develop medicine range identify characterise taar family bruton tyrosine kinase inhibitor btki mechanism key approach achieve neurological disease include alzheimer disease receptor start block bcell signal result excessive functional cure hbv molecule include parkinson disease pd huntington disease forefront development selective taar immune response see autoimmune disease viral rnatargeting compound early development autism spectrum disorder asd multiple sclerosis agonist compound study ambitious phase ii trial ra invent inhouse comprise lock nucleic acid ms schizophrenia spinal muscular atrophy lupus ra trial innovative sevenarm lna chemistry gain acquisition sma work regulator initiate phase ii trial sma oral study headtohead comparison current santaris pharma novel lna platform payer concern new trial design new molecule offer novel mechanism action mrna standard care initiate phase ii trial allow access previously impenetrable pathway endpoint order support approval disease splicing modulator tackle debilitate ra cadherin antibody believe disrupt different disease attack disease modify medicine eventually fatal genetic neuromuscular disorder tissue cell interaction drive inflammation target level rna protein common geneticallybase cause nonimmunosuppressive manner addition begin asd continue invest heavily novel infant death amyotrophic lateral sclerosis al phase ii study treatment sjgren syndrome antibacterial resistance focus novel vasopressin va receptor antagonist progressive neurodegenerative disease know illness approve treatment target novel approach develop antibiotic lou gehrigs disease begin earlystage study common rheumatic autoimmune disease aim cure severe multidrug resistant novel molecule believe inhibit pathway lead internally discover cathepsin inhibitor design bacterial infection nextgeneration betalactamase advance image technology enable neuronal cell death implicate al roche interfere specific immune pathway dysregulate inhibitor nacubactam broadspectrum antimicrobial working find medication chronic pain multiple autoimmune disease time activity combine betalactam antibiotic well understand biology increase potency improve safety limit leave intact pathway immune system dual mechanism action effectively inhibit addiction see current therapy collaboration involve example fighting infection wide range betalactamase enzyme responsible nervous system disorder xenon pharmaceutical continue develop humanise complement inhibitor c monoclonal antibiotic resistance inhibit certain bacterial roche science innovation science innovation roche pharmaceuticals clinical pipeline phase phase ii phase iii registration oncology inflammation immunology cell wall enzyme compound currently learn move fast lead phase development grant fda fast way smart drug development track designation recent collaboration neuroscience agreement biomedical advanced research nature personalise healthcare mean development authority barda patient population small treatment grow nuanced continue ophthalmology feedback loop dependent confluence science infectious disease highly innovative bispecific monoclonal anti data access datum vegfang antibody rg research development clinical trial investigation wet agerelate macular degeneration advanced genomic sequence modern diagnostic enter phase ii study diabetic macular oedema test realworld source like electronic ophthalmology twopronged drug develop proprietary medical record patient registry window crossmab technology bind vascular endothelial collective experience patient growth factor vegf arm bispecific world add significantly knowledge allow monoclonal antibody angiopoietin ang build decade lampalizumab understand disease core unlocking phase iii study geographic atrophy power datum set industry precedent ensure quality validity consistency pipeline new molecular entity nme cover broad range disease highly innovative technology apply create produce active molecule inherit genetic rare disease number bracket refer personalise healthcare project include diverse technology invent molecule internal expert external partner medicinal property believe pioneer new approach biomarker analysis difference patient certain inherit genetic modern safety assessment approach nextgeneration disease know rare disease sequence artificial intelligence advanced case inherit genetic disease manifest analytic bring holistic understanding innovate clinical trial feed refine trial well identify infancy childhood lead childhood debilitation datum afford deeply fast decade development activity drugcentric potential drug combination immunemediate early death urgent need develop insight science tell approach focus prove clinical benefit onesizefitsall disease multiindication approach therapy patient limit combines knowhow immunology genomics medical landscape science patientfocuse allow early sign efficacy available treatment option sma huntington create database information immune strive drug development study compound cathepsin inhibitor disease example inherit genetic disease cell accessible researcher direction precision target example test treatment sjgren currently develop candidate generate exciting crosspollination collaboration medication diagnostic identify subgroup syndrome parallel small number therapeutic collaborative partnership scientist work overlap pathway patient particularly cit demand raise patient celiac disease believe target researcher work cancer immunotherapy bar clinical trial design create similar immune principle apply smart agile product development cit instance try turn immune study simultaneously test single drug multiple pace progress medicine offer new hope system study rheumatoid arthritis disease test drug single disease furthermore decision drug development patient deliver wave paradigm autoimmune disease seek dampen immune condense traditional threephase clinical increasingly reflect voice patient shift therapy faint heart require response share insight valuable trial fluid adaptive process effort allow paperwork protocol dose delivery new approach develop drug team addition benefit database develop bring right safe medicine method proactively introduce perspective break new ground novel technology integrate internal data datum generate right patient efficient manner cit core heart work cuttingedge analytic capability leverage external expert example pilot sophisticated trial design biweekly visit doctor office example pipeline combine strength pharmaceutical diagnostic feature continual evaluation array datum patient sma al go hardship rochecompipeline roche science innovation science innovation roche preferable subcutaneous intravenous create value transformative partnership neuroscience roche sign license agreement antibacterial resistance million people intramuscular injection know challenge roche long value external innovation chugai sa antiil receptor monoclonal project die untreatable bacterial infection patient sma al participate clinical critical component rd strategy significant antibody currently investigate pivotal roche leverage decade infectious trial design study devastating proportion sale drive product bear phase iii study neuromyelitis optica spectrum disease research help address threat team disease valuable input patient research partnership current disorder nmosds rare autoimmune disease pharmaceutical diagnostic division caregiver similarly collaborate closely pipeline comprise partner product central nervous system characterise mainly embark landmark alliance patient association alzheimer disease asd collaboration critical realise inflammation optic nerve spinal cord authority barda involve study neurological disorder study novel treatment potential personalise healthcare enhance approve therapy nmosd generation betalactamase inhibitor potentially area lucentis current standard pipeline key disease area exceptional confused multiple sclerosis time breakthrough antibiotic cure drugresistant severe care retinal disease explore alliance therapeutic diagnostic diagnosis sa offer potentially bestindisease infection vitro diagnostic capabilitie innovative delivery mechanism alleviate technological area help well understand treatment nmosd add grow portfolio burden patient visit doctor leverage complex biology find new drug candidate treat people neuroinflammatory disorder oncology increasingly collaborate regular intravitreal injection good use grow volume genomic external partner particularly cancer immunotherapy realworld datum immunology research role explore drug combination rationally realworld consideration innate immune response trigger autoimmunity design maximise therapeutic benefit clinical superiority demonstrate partner roche build culture grow area interest roche tailor biology associate patient tumour value product everyday setting listen carefully potential partner enter early rd collaboration monash enter new clinical collaboration realworld consideration increasingly important creatively structure collaboration meet university melbourne australia focus agreement develop lead immunotherapy drug ensure product accept national party need choice drive search novel innate immunity checkpoint modulator tecentriq broad number haematological policymaker adopt medical practice partner share passion innovative discover monash principal investigator solid tumour type addition announce dimension add development complexity science look opportunity address unmet consider leader space antist collaboration biontech germanybase large proportion drug pipeline medical need potential revolutionise investigational medicine inlicense amgen biotechnology company develop manufacture instance develop sophisticated standard care finger complement exist rd programme commercialise novel messenger rna mrnabase treatment schedule advanced diagnostic pulse emerge science alliance strengthen respiratory portfolio antist individualised cancer vaccine hanmi needs country radiation lead academic entrepreneurial investigator potential good class patient establish innovative drug company korea devices cool apparatus laboratory capacity small large value partnership equally highneed asthma chronic obstructive pulmonary develop novel panraf inhibitor accommodate specific need different disease ilmediate disease country subtle treatment variation major enter number transformative academic alliance work economic disparity make great stride partnership enter option agreement distinguish scientist cuttingedge project understand medical care deliver novimmune ni antitlr tolllike lead institution harvard university globe ensure medicine ophthalmology new alliance help extend receptor investigational medicine advance massachusetts institute technology cambridge deliver tangible benefit patient worldwide scientific leadership retinal disease sign scientific understanding cellular molecular university max planck institutes swiss federal license agreement biotherapeutic immunology guide development potential institute technology collaboration cambridge novel antiil monoclonal new treatment believe ni potential seek find develop new molecule invent new partnership help stay line antibody combination standardofcare bestinclass therapy treatment research tool advance understand antivegf therapy position firstinclass rheumatoid arthritis autoimmune disease disease mechanism innovation treatment wet agerelate macular degeneration diabetic macular oedema amrrevieworg roche science innovation science innovation roche dr amy abernethy flatiron health advance cancer treatment cancer researcher clinician caregiver capture datum million unique vantage point fight cancer patient cancer care provider open year work practice oncologist new vistas physician scientist spend career duke university partnership roche help accelerate serve professor medicine head programme addition collaborate cancer care research program join design clinical trial promise new flatiron health see opportunity cancer treatment profound difference bring field medicine technology roche flatiron share vision personalise healthcare resonate secretary flatiron found premise leverage board personalise medicine coalition big datum help researcher discover effective flatiron work roche strategic partner therapy well match cancer patient foundation medicine analyse variation lifesave treatment human genome find target cancer therapy step collaboration truly exciting gleaning insight realworld evidence combine realworld evidence genomic analysis today cancer patient cancer patient learn therapy work well enrol clinical trial datum individual principle source analyse treatment effective provide clue physician come human develop future therapy impact work patient lose patient cancer undergo battle skin cancer ask use insight treatment access clinical trial tumour tissue family history melanoma treatment help owe flatiron focus cancer patient patient good use pearl capture realworld datum information leave oncocloudtm platform help train expert unstructured data medical daughter know limit case note xray pathology report today medicine father suffer transform validate information extremely difficulttotreat cancer video registry strict procedure ensure underscore urgency rochecomarbio quality entry patient anonymity find effective oncology treatment roche access healthcare access healthcare roche acce material topic cover chapter healthcare growth strategy emerge develop market sustainable healthcare pricing disease awareness treatment education design access programme country level support healthcare system improve diagnosis educate build contribution un sdgs local skill address affordability issue measure blood glucose level high degree accuracy precondition managing diabete successfully roche access healthcare access healthcare roche g round breaking advance medical science meaningful reach patient today million people globe make progress long way lack access essential healthcare service access difference ground need disease awareness modern tool reliable fast diagnosis key factor successful medical intervention healthcare big challenge society deep understanding challenge face work partnership individual healthcare system systematic address multidimensional challenge improve comprehensive approach identify key aspect healthcare especially hurdle right stakeholder order develop million people country reduction like live disease challenge patient treatment complex disease like cancer access tailor effective solution reach patient average timetotreatment family face role diagnostic hospital cancer patient beneficial partnership broad spectrum stakeholder treatment play manage disease aim train oncologist turn access diagnostic essential improve access healthcare people awarenessa crucial factor success support voice patient foster constructive test disease effective accompanied need date develop access plan awareness disease symptom essential healthcare debate education awareness total clear proposal overcome access screen early detection support barrier particular country plan major focus connect country patient organisation represent patient view believe responsibility improve access integrate local business ensure continue good practicesharing find example issue surround healthcare include timely need work sustain support demonstrate ongoing people philippine deal equitable access treatment help shape partner resource world commitment market integral similar issue people venezuela current future healthcare environment make ability help facilitate change business model different geography unaware patient voice hear strengthen commitment widen access approach hold summit industry partnership access accelerate access healthcare complex challenge dedicate develop sharing access good practice exchange knowledge idea bring biopharmaceutical company believe key factor need place globe find good way promote th annual international experience exchange leverage innovation expertise resource successful treatment awareness diagnosis healthcare access programme collaboration patient organisation ieepo large global patient address treatment noncommunicable disease capacity fund wide array different geography similar hurdle virtual organisation meeting fully sponsor roche ncds disease cancer heart initiative support area improve access community share question idea hold copenhagen denmark march disease significant grow problem low medicine test include work develop online case study library greatly overarch theme innovation record total lowmiddle income country nearly government disease awareness campaign train support implementation local access plan delegate country attend ieepo death kind disease occur access lab technician sophisticated diagnostic training come year accelerate multiyear programme facilitate community healthcare worker provide flexible key factor need place cooperation healthcare stakeholder pricing solution patient organisationsvital partner achieve tangible impact improve access patient patient organisation essential successful treatment awareness diagnosis treatment care ncds thank argentina comprehensive local programme partner roche share common vision focus diagnostic medicine implement lead expansion improve patient access innovative treatment healthcare capacity fund healthrelate datum expertise oncology treatment coverage approximately service help understand range area relate access whointmediacentrenewsreleasesuhcreport whointmediacentrenewsreleasesnoncommunicabledisease roche access healthcare access healthcare roche dramatic impact hiv response life expectancy age world zimbabwe uganda kenya swaziland session focus innovative way value access innovative healthcare south africa empower involve patient example health solution stakeholdersa true example botswana technology assessment hta patient centricity patient empowerment subsahara drug development clinical access process crucial want help patient organisation success idiopathic pulmonary fibrosis respective conversation local level roche supporter european idiopathic pulmonary fibrosis group work base ieepo model focus ensure write declaration call country regionspecific topic roche organise improve access treatment accept africa tragically infant hiv die subsaharan africarequire particular focus experience exchange patient organisation european parliamenta goal achieve birthday help diagnose combat hiv continue implement africa strategy local level eastern europe middle special moment affect infection child adult roche partner involve develop tailor solution east africa eemea region conduct second devastating disease associate low life unaid clinton health access initiative local partner annual eemea experience exchange patient expectancy lack awareness diagnosis issue president emergency plan aid relief organisation latin america patient treatment delay trust open new chapter global fund global access programme access country beset unexpected group workshop health policy april disease continue support initiate large infant testing programme challenge shipping medicine example patient organisation exchange subsaharan excellent work patient organisation area world feature dry blood sampling product ship special large africa take place abidjan cte divoire patient diagnostic techniqueto date seven million cargo box maintain low temperature group representative country take unique diagnosisvital effective therapy infant test hiv require cancer medicine opportunity share good practice strategic diagnosis disease complex vital practical delivering medicine remote planning fundraising communication ensure right treatment choice roche global access programme location accessible small aircraft work global local country partner concert approach support unaid combat specialist roche invent new small cold chain roche support training patient organisation include local government nongovernmental hiv impact unaid programme go box significantly improve situation membership european patient organisation ngo patient organisation access compelling body ship country africa academy therapeutic innovation patient healthcare company find tailor solution evidence document extraordinary health region world lead project paneuropean innovative medicine barrier diagnosis access engage economic benefit accrue success initiative firstyear expertlevel online global health institution world fight hiv result scaledup hiv treatment goal increase access innovative training course show impressive result health organization address key global service overall life expectancy subsaharan africa treatment patient globe whilst create prior training trainee advise health challenge sharply increase receive antiretroviral longterm sustainable business environment regulatory agency advise htasthese therapy lead remarkable improvement quality figure jump respectively month roche able support novo nordisk life people live hiv substantially fund innovative pricing solution finish course consequently change diabete child programme improve economic prospect fund healthcare investment reimbursement individual trusted partner discussion example provide free blood glucose monitor medicine test critical protect patient tool test supply education healthcare support healthcare capacity financial burden current economic environment professional people diabete healthcare capacity require train team work increase demand healthcare system result scaledup hiv treatment caregiver seven country africa right equipment provide good making challenging payer fund late child reach date chance successful treatment fundamentally treatment option patient service overall life expectancy sub clinic establish healthcare believe deserve access medicine flexible pricing approach include professional train region currently access differential pricing support patient access saharan africa sharply increase united nations population division world population prospect rosen et al effect antiretroviral therapy patient economic wellbeing fiveyear followup aids lifson grund b increase quality life immediate art initiation result start trial conference retroviruse opportunistic infection roche access healthcare access healthcare roche collaboration private insurance company provide increase access cancer care support development new private insurance policy cover pipeline additional cancer therapy cancer insurance policy cancer insurance millions global regional medicine scientific clinical insight lead coverage cancer develop effective medicine insurance product global pipeline country involve partner involve multiple indication combination estimate number continue grow drug benefit patient vary believe different benefit furthermore currently explore option reflect way medicine price mark expand initiative cancer funding shift traditional approach pricing start explore expand scope area cancer insurance product development multiple provider number people gain access cancer care expect grow strongly medicine pack vial implement molecular diagnostic test multiple sclerosis personalise reimbursement model prm diabetes currently run prm pilot europe currently work global regional country demonstrate flexibility partner country include direct insurer generation collaborate center august agreement sign kenya system approach work ensure reinsurer benefit collaborate right disease control prevention training ministry health roche herald start require infrastructure place expect partner able replicate successful generation lab technician benefit activity include breast cancer awareness prm implement couple year insurance product region new healthcare project management knowhow programme improvement screen countrybycountry basis country insurance product pipeline tremendous diagnostic division act catalyst diagnostic train new oncologist report success potential expand coverage million bring hospital builder medical device company oncology nurse support development people prove success approach region bestpractice national treatment guideline private insurance complement public model replicate company increase number cancer treatment centre healthcare system organisation healthcare system formal agreement memorandums kenya access medicine available work private insurance company understanding sign subsaharan patient treat public institution meaningful impact patient access diagnostic focus partnership progress africa country include ghana kenya follow government kenya roche jointly cover treatment create private funding africa strategy roche improve agreement cte divoire aim cost solution country public coverage step patient journey address agreement improve access timely inadequate work local insurance key access factor awareness diagnosis healthcare precise diagnostic service treatment partner breast cancer initiative company partner focus cancer coverage capacity funding aim bring quality highquality care widely available hold summit march offer breast cancer enable launch private insurance healthcare african regardless education multidisciplinary team healthcare product country like china india portugal live ability pay work goal ghana agreement ministry health professional subsaharan africa event vietnam thailand late thoughtful multidisciplinary approach sign improve access care people ghana welcome attendeesinclude surgeon type cancer insurance policy available partnership collaboration investment breast cancer viral hepatitis sign radiologist pharmacist nurse oncologist different country million people empower local healthcare provider initiative include set disease awareness academic public hospital different programme conduct screening promote early country team work identify gap fundamental barrier region detection establish centre excellence respective institution prioritise need contribute subsaharan africa lack basic infrastructure improve diagnostic facility treatment centre develop month action plan improve eg access hospital clean water limited training specialist develop national cancer patient care strengthen centre excellence type cancer insurance policy availability treatment adequate care registry well understand disease burden clear roche remit build hospital work establish national treatment guideline different country provide coverage hire physician roche contribute support training healthcare professional support million people pragmatic epidemiology sociodemographic data fredhutchorgenlabsphsprojectsbreastcancerinitiativehtml roche access healthcare access healthcare roche marianne gilchrist swiss join force address oncology need china grow insurance industry year datum lifeblood insurance industry father work scottish life assurance roche find partner provide company age afterschool job accurate information incidence cancer filing life insurance policy safe scottish disease progression treatment pathway life head office edinburgh scotland associated cost allow work local international insurance company design finishing degree oxford work policy cover oncology treatment able year financial service marketing calculate risk insurance company run advertising discover affinity asia sustainable business offer individual realise world insurance affordable premium truly feel sense purpose break path study clinical reinsurance company swiss take psychology set private practice singapore risk reward important note learn year serve insurance policy china stipulate sure continue use company productsthis expand overall access treatment join swiss head health solution asia private insurance develop addition datum roche provide education country asia healthcare cost program cancer prevention leverage pay pocket illness cancer connection lead physician wipe lifetime saving insurance agent basic understanding oncology swiss work government regulator help close societys protection gap ensure patient understand policy china cancer leading cause death buy coverage need number shock million fatality million newly diagnose case opportunity open private insurance year oncology treatment cover china collaboration roche illustrate governmentprovided healthcare swiss see creative approach close societys protection opportunity address treatment gap gap demonstrate power crossindustry unable partner partnership improve access healthcare roche chen w zheng r zhang et al cancer statistic china j clin roche people people roche people material topic cover chapter employee engagement talent retention compensationbenefit leadership commitment employee make valuable difference patient organisational effectivenesss commit good work contribution un sdgs integrity courage passion diversity inclusion vital foster innovation encourage different perspective idea thinking style strive create work environment include facet diversity roche people people roche w orke roche mean job opportunity difference think act boldly global community talented people engagement roche successful career great work environment employee roche distinct special people feel value respected south san francisco employee volunteer total hour donate usd genentech give week highly engage people deeply connect purpose patient time ask employee opinion need able achieve high standard measure engagement regular global employee survey act result diversity inclusion foster innovation result reflect progress roche provide people reward enriching building well place work fundamentally believe innovation come key position diagnostic fill woman experience mean focus thing leverage diverse perspective talented end figure rise matter respect diverse perspective recognition give local community people strive create work environment expand programme include celebrates success healthy risktake present country include facet diversity age gender race experience develop region leader embrace value leadership world proud local community ethnicity sexual orientation religious affiliation provide element reverse mentoring allow commitment development enable meaningful headquarters basel visible difference educational sponsor gain deep insight site engage variety way support background professional knowledge personality challenge opportunitie new give local community type thinking style life experience emerge market consistently vote great place work employee south san francisco example leadership commitment increase employee experience participate different form organise volunteer genuine interest people emphasise establish develop region employee external institution consistently rank activity clean school working importance person uniqueness global presence critical employer choice roche genentech local food bank weeklong period call importance person feel team understand specific challenge circumstance recognise forbe america company genentech give total project engage inclusiveminde leader market operate want work rank second biotechnology list complete volunteer special launch inclusion index pharmaceutical increase number employeesparticularly renowned organisation great place work institute week involve nonprofit organisation division ask employee leaderswho experience establish employer institute place roche good place total hour volunteer building respect gain trust develop region thing support work list number year country include usd donate employee hallmark inclusive organisation international assignment help individual gain brazil china denmark france germany italy mexico poland index measure inclusion rochewide experience assignment spain switzerland uk read community engagement chapter global employee opinion survey geo develop region look experience hiring hire key diagnostic division pioneer programme leadership position develop region experience provide opportunity highpotential woman bring diverse experience capability systematically acquire sponsorship establish company ensure leadership readiness pathway valuable feedback continue growth market career progression approach effective roche people people roche people fiveyear goal base figure develop leader representation woman foster strong leadership key leadership role representation people establish want people great leader executive leadership programme develop region experience key leadership role instil value act role model assess major trend change healthcare foster accountability leadership commitment environment growth digital healthcare level company order focus new leadership capability quartile continuously cultivate leadership culture offer require leadingroche broad portfolio tailormade leadership development participant report positive leadership change rank overall employee engagement score option enhance leadership competency skill month participant measure global employee opinion survey manager say notice positive leadership addition local course leader change employee month attend global leadership development programme genentech launch initiative call leadership goal baseline include initiative lead excellence enable leader evaluate leadersroche lead peopleroche live promise leadership commitment company value want increase number programme push boundary outside see longerterm leadership leadership commitment classroom example njia impact njia year group travel leader experience mean path kaswahili programmelaunche tanzania roche participant agree genuine interest people involve roche leader travel profound impact leadership behaviour establish develop region listen carefully tell truth explain tanzania working partnership local mindset tanzania campaign result empower trust people decision nongovernmental organisation ngo address programme increase awareness cervical discover develop potential people current healthcare challenge country cancer screening lead new funding strive excellence extraordinary result leader gain ontheground insight need operate allocation nursing staff training set priority simplify work emerge market work ngo congratulate people job partner implement sustainable solution locally roche people people roche employee worldwide europe north america asia attract retain good talent provide space innovation cultural diversity growing emergence offer numerous additional benefit andor multigenerational workforcewhich mean amenity employee vary site site latin america africa australianew zealand generation people work include pension scheme health insurance officei increase million woman childcare medical facility flu vaccination preventive enter global workforce come year health screening discount local retailer great place work attract good people transportation tofrom workplace align value purpose paramount continue success accommodate individual circumstance employee operate unit employee function support flexible working model actively rewarding recognise employee use country enable employee work roche pharmaceutical roche diagnostic marketing distribution research development service effort strike attractive balance home buy sell day job share highly competitive base salary performancelinke see particularly sharp increase utilisation reward flexible benefit tailor different flexible working model allow work parent chugai corporate manufacturing logistics general administration need key focus roche connect balance personal time work time programme promote ownership partnership optimal way latin america circumstance roche allow employee purchase roche demand great accommodation roche stock discount price country create regional flexible benefit programme incorporate china initiative allow additional alternative compensationsuch see high participation rate launch fuel voucher area fuel shortage hire promote diverse group talented people furthermore proactively encourage help new idea innovative solution scientist publish work want year applause flourish great research opportunity build programme online tool employee use external reputation engage promote employee wellbee recognise directly ecard remain goal hire retain great scientific mind reward point nomination overall usage good scientist world live find balancean initiative foster launch peertopeer expand recruitment effort ultimately commit cultivate rich culture health wellbee roche employeeswe recognition employee traditional university actively collaborate work environment allow individual promote awareness education healthy life style academic institution attract good talent thrive difference patient nutrition emotional wellbeing offer resource give people space innovate offer number internship post gym sport club medical service counsel yearly recent year challenge think doctoral research position global wellbeing week initiative involve find good people identify participation site nurture potential assess performance read harukus story target initiative leader well equip number employee express fulltime equivalent roche people people roche haruku shirahata university tokyo exciting real contribution start december raise work able identify potential efficiency hand laboratory work university gain reduce waste tokyo professor hirokazu sugiyama department chemical system engineering supervisor approachable open ask candidate new internship programme discuss project answer question roche switzerland lunch coffee break opportunity network discuss idea meet new people little nervous leave home academia time find courage ahead internship clear diversity begin twomonth internship august important roche colleague happy time live outside japan away japan team value family lot new share input please half apartment basel intern commute employee kaiseraugst woman day kaiseraugst roche produce drug treat cancer hepatitis disease university tokyo pursue master degree doctorate chemical engineering play valuable role experience roche bring close day plant manager welcome new impact work patient convince intern employee emphasise choose right career path single play important role produce lifesave medicine patient right handson experience show begin aware teamwork engineering add value team pharmacist important chemist specialist come make process efficient environmentally facility liquid sterile drug main friendly exciting real contribution project optimise batch production rubber material stopper glass vial syrinx definitely recommend programme rubber material critical maintain student key get sterility pharmaceutical product feel experience extra effort ask question truly difference make product safe share thought engage people patient contribute sustainable remember contribution batch production proud difference live patient roche safety health environment safety health environment roche safety health e nv ironme not material topic cover chapter strive ensure safe work environment occupational accident protect health employee emphasis environmental responsibility sustainability allow expand business contribution un sdgs minimise ecological footprint remediation kesslergrube landfill site grenzach germany modern safe remediation method protect water nearby rhine river serve source drinking water approximately million people downstream roche safety health environment safety health environment roche w e significant progress increase use renewable resource procedure safety security health site frequency proportionate environmental protection embed risk conduct training programme solar power plant genentech oceanside facility expect provide site total electrical power requirement operation important component roche employee total employee sustainability concept high standard participate hour dedicated training area build solid foundation prevention average approximately hour employee continually improve site infrastructure enhance focus security employee health safety efficiency reduce environmental impact ensure occupational health safety protect employee physical asset critical expand successful business commit essential category work roche information integrity brand improve track record monitor result safe task urgent complex routine product principal concern roche preventive progress ensure compliance standard aim minimise number work day lose measure priority aspect security objective aim cover occupational accident employee year key performance indicator roche accident rate rar number focus introduction new accident cause absence work lose time roche security incident reporting tool improve monitoring performance accident rate ltar work hour global platform reporting incident issue company complex production operation track achieve safety goal occur application allow affiliate affiliate world roche expose rar ltar despite group security gain thorough overview global risk range dependency limit preventive measure employee drown adverse event loss occur safety health fossil fuel source energy access clean take water sport activity year focus measure train base environment water worstcase scenario fatality company event profoundly regret tragic lesson learn rochecom mitigation plan help reduce risk accident offer sincere condolence environment invest innovative technology perform audits victim family friend second security focus eastern europe security workshop hold budapest hungary illness rate accident rate rar site security officer eastern european site losttime accident rate number workrelate accident discuss challenge good practice key working day lose year accident fiveyear goal topic region prevention response counterfeit product information security minimise ecological footprint risk intellectual property measure aware business dependent protect train adequate security increasingly scarce natural resource measure small affiliate commitment sustainable development duty responsibility use new sustainable technology process ecobalance energy consumption water consumption general waste minimising impact environment roche safety health environment safety health environment roche emission water primary energy emission air mainly co roche ecobalance landfille waste reduce air pollution raise averagesized home community water consumption awareness environmental protection course year lease oceanside noise encourage sustainability solar facility save usd year energy cost decrease energy energy consumption terajoule building stationary equipment gas fuel oil waste electricity district heating roche group total scope roche depend nonrenewable resource joint district heating cool c renewable scope share sustainable energy vulnerable company supply constraint heat c groundwater instead steam energy volatile market price set energy chiller scope save action plan site innovative replacement compress air system consumption technology upgrade infrastructure energy recovery technology gjemployee example large solar panel array start operation scope facility oceanside cover term energy represent reduction heat business flight site electrical power similarly instal consumption gj steam gj datum collect group gj gigajoule additional solar panel array site kaiseraugst c renewable heat reduction goal locate close basel compress air reduction co emission tonne replace fossil fuel renewable energy nonsustainable sustainable reduce carbon footprint purchase large proportion energy operation energyefficient equipment include hybrid car measure impact environment currently come fossil fuel source oil natural capital increase sustainable energy supply ecobalance metric develop swiss federal gas work maximise efficient energy complete pilot test new natural monitoring employee travel need work process office environment want usage increase use sustainable energy whilst capital protocol internationally agree framework project complete improve ecobalance compare continue expand global business long set business measure monetary result avoidance tonne co improvement decrease energy consumption term goal reduce energy consumption value environmental impact dependencie emission lead estimate cost air emission volume consume water employee approximately compare society natural capital saving chf million year reduce weight general baseline level energy consumption assessment nca undertake include high level chemical waste lead improvement decrease sale grow assessment roche overall value chain prove roche basel site develop energy vision achieve result despite useful highlight complex broad spread initiative support corporate goal continue growth business midterm goal reduce consumed energy natural capital dependency impact reduce energy consumption increase scope scope source employee study involve detailed assessment use renewable energy innovative technical internal idea trigger significant improvement facility plan roche operational site switzerland outcome solution mean huge monetary saving encourage welcome suggestion increase proportion sustainable energy demonstrate natural capital perspective roche equally beneficial environment employee improve sustainability culture compare level genentech swiss site manage good example energy vision action performance hold seventh facility oceanside help substantial significant societal impact greenhouse gas renovation staff restaurant edition ecompetition result idea progress goal completing emission roche carefully manage basel headquarters lead saving submit winner past ecompetition solar panel array project consist material issue assess result approximately chf submission help improve different panel provide site total protocol study compare exist eco insulation optimisation building area include energy conservation waste reduction electrical power requirement capacity balance methodology societal impactmonetary decrease consumption water raw material megawatt solar plant power valuationresult find highly comparable roche safety health environment safety health environment roche co equivalent emission metric tonne landmark deal nearly country agree work implement programme phase hydrofluorocarbon powerful increase efficiency water usage genentech ghgs see significant step curb south san francisco site employ innovative scope global warming approach reduce water withdrawal improve fuel combustion wastewater management site halogenate hydrocarbon recognition programme reduce emission reuse approximately reverse osmosis reject scope ghgs mitigate climate change water cool tower cool tower use pre identify global leader action equivalent approximately water marketbase strategy award position global year approximately year come locationbased climate list develop cdp carbon reject water implementation total scope marketbase disclosure project environmental initiative lead incremental scope saving amounting usd business flight halogenate hydrocarbon tonne energyintensive utility water usage discharge waste inventory change report methodology number different report compress air liquid nitrogen consume water withdraw million cubic metre global inventory include chugai genentech ventana water consume ecobalance score effectively validate improve energy efficiency relevanta million cubic metre approach study conclude ncas reduction ghgs employee tenyear environmentally sustainable product wastewater discharge provide roche valuable insight enhance period absolute scope consider entire lifecycle product treatment plant decisionmake well manage risk scope ghg emission cut term environmental impact aim million cubic metre opportunity contexts include reduction achieve implement energysave safeguard ecosystem protect business organic matter example relation water management water measure reduce fuel use longterm financial reputational risk discharge waterway scarce region heat cool operate site key contributor mabtherarituxan avastin herceptin perjeta treatment tonne success site oceanside switch lucentis monoclonal antibodie heavy metal discharge increase energy efficiency reduce co solar power generate chf billion sale waterway business continue grow committed low excretion rate judge treatment kilogramme maintain low level emission air halogen halogenate refrigerant fire respective authority present significant achieve far make improvement suppressant ghgs remain risk sewage work surface water feasibility study ongoing method manufacture site emission air atmosphere long period time term benign nature constitute treat manufacturing processing equipment nitrogen oxides sulphur dioxide particulate commit reduction use environmentally sustainable compound surface superhydrophobic decrease respectively halogen year create selfcleane effect protein emission volatile organic compound increase addtion reduction achieve manage limited water resource emission air site low legacy roche site continue examine available water usage remain relatively unchanged recognise leader corporate level mean new process activity alternative work refrigeration fire year procedure ensure efficient time sampling result large suppression supplier achieve reduction water use whilst allow business continuity action climate change result temporary fluctuation majority importance approach parallel goal reduce water consumption employee greenhouse gas ghg emission originate agreement take united nations environment weight accord water stress commitment protect natural resource transformation use energy goal programme meeting kigali rwanda october respective region end roche site roche safety health environment safety health environment roche sustainability protection people cellular debris remain solution adhere activity kesslergrube grenzach germany determine create longterm social metal surface modification target environmentrelate activity genentech value community continue environment priority reduction water cleaning site south san francisco oneoff activity remediation programme previously day simultaneously reduce usd million contribute tonne generate landfill site site nutley roche spend cleaning year furthermore self term regular production reduce agreement reach hackensack university cleaning surface reduce need phosphate low volume chemical waste health network seton hall university create cleaning process decrease general waste incinerate landfille medical school site roche environmental impact discharge nearby decrease retain responsibility environmental cleanup complete excavation body water support global effort divestment start end year thank careful kesslergrube water protection aim reduce total wastewater activity optimise packaging supply plan roche ensure safe efficient kesslergrubede toxicity select production plant chain way side atlantic set infrastructure necessary execution complex programme reduce perimeter versus level approximately half water roche kaiseraugst site optimise remediation kesslergrube landfill site emission minimum draw cool circuit procedure deliver small quantity material water chemically contaminate analyse c temperature change shipping box directly discharge furthermore allow efficient agile shipping discharge wastewater pollutant able cope small quantity small comply fully relevant regulation include change aid business continuity mitigate risk pretreatment requirement transportation capacity restriction addition leave dr richard hrzeler roche boris krause friend earth germany dr tobias benz mayor grenzachwyhlen samer hijazi bauer umwelt gmbh initiative reduce freight cost use packaging discuss progress remediation activity kesslergrube germany minimise waste maximise recycling material reduce material waste co emission aim implement follow waste management small change result approximate strategy activity avoid reduce reuse saving chf genentech south san recycle thermally destroy permit landfilling francisco propose process make resort inert packaging supply chain far complex cutting material slag ashe depend consolidate number shipping box availability suitable local wastetreatment plant save usd million cutting co dispose nonhazardous general emission reduce shipment waste authorise landfills objective avoid disposal chemical waste hazardous material waste tonne landfill site accept responsibility waste generate operation include waste previously deposit site landfill general waste baseline aim reduce general waste employee generate landfilling organic chemical chemical waste chemical waste incinerate land fill generate increase largely remediation construction waste substance chemically reactive roche safety health environment safety health environment roche ali afghan genentech join company help save life leave iran follow brother recover leukaemia want emigrate courageous mother disease tragic event raise boy single parent insist family precede year transform begin high educationbut limited ask matter academic opportunity iran time earn bachelor degree general science new chapter mechanical engineering portland state retire intel decide use university pursue career engineering include skill experience help come year intel get marry opportunity join company help beautiful daughter save life lifechange news progamme director genentech go routine medical checkup huge project upgrade facility south san doctor detect elevated white blood cell count francisco environmentallyfriendly cool refer specialist give shatter system make contribution well diagnosis chronic lymphocytic leukaemia cll planet daughter child stage like hit wall mile hour world stop parallel ask speak group employee experience leukaemia patient not remember vividly doctor show bell easy open private life curve average survival rate year people speak old man cll late group time hear people comment not reliable data survival chance experience cancer patient touch inspire make difference pull not let family daily work generation lifesave friend start chemotherapy medicine come unexpectedly combined rituxanmabthera roche monoclonal clear story patient antibody target specific lymphocyte way give people video month treatment doctor give exhilarating help rochecomarpat news body free cancer new lease life roche community engagement community engagement roche community e ngage not material topic cover chapter collaboration international local partner community engagement support programme result last improvement sustainable benefit community contribution un sdgs operate society general schoolchildren perform chemical biological experiment experio roche school laboratory kaiseraugst switzerland roche community engagement community engagement roche f century philanthropic engagement focus build strong healthy community operate believe role good corporate citizen support social cause science education provide longterm disaster relief programme art cultural project community experience major roche start partnership maharishi institute johannesburg south africa cover universityeducation cost student aim lasting impact people live natural disaster especially develop world support project result last sustainable focus address need community benefit initial emergency phase partner roche operate philanthropic local authority relief organisation help philippine complete support develop world develop activity select manage locally roche affect community rebuild prepare project open arm foundation country case respect independence affiliate world work partner future contribution range product provide costeffective solar light source people autonomy partner area research share commitment longterm solution donation logistical support transfer rural slum area continue affect education objective strengthen community knowledge expertise aftermath typhoon haiyan sustainably expect partner share risk develop area fund education programme commitment investment resource example humanitarian engagement haiti devastate earthquake support talented student disadvantage implementation project nepal experience earthquake support construction disasterresistant background start partnership affect million people destroy school partnership swiss agency maharishi institute south africa cover corporate level supplement local activity home local management centre development cooperation school universityeducation cost student additionally need support area roche respond donating vial antibiotic open sustained hurricane matthew roche south africa support health education operate manage longterm international phase approach partner october unaffected wellness programme student career development programme world wildlife fund nepalese government personal finance workshop employ transnetphelophepa healthcare train mobile local organisation support rebuild pakistan partner citizen graduate learnership programme clinic bring medical care medicine community ecosystem langtang national foundation year establish people year remote area south park work twoyear build nepal extend primary school rural jacobabad nepal partner habitat africa project habitat humanity international build follow extensive flooding area roche children walk worldwide fundraise support rebuild humanity international world employee project initiate support salme municipality nuwakot district investing education children initiative malawi see house destroy earthquake believe longterm impact education wildlife fund local authority community world project help cover urgent need improve life child roche continent partnership salzburg family provide access safe disaster family community belong help rebuild community ecosystem festival launch encourage resistant housing solution partnership local institution support universitylevel student explore common education programme design inspire child earthquake ground innovation art science youth primary grade university roche community engagement community engagement roche open experio latin america support fundacin educacin lead local academic organisation include foster interest research peru colombia el salvador guatemala hong kong education city hong experio roche school laboratory open roche school laboratory receive goal develop middle class roche provide kong university science technology school february kaiseraugst switzerland year scholarship student study engineering science joint roche pharmaceutical auspice human resource apprenticeship visitor economic lead collegesuniversitie india roche diagnostic initiative science competition department stateoftheart laboratory support collegeuniversity scholarship mentorship programme aim encourage design enable pupil region student kiran children village home secondary school student use science acuman primary school college experience practical school childrensome disability innovative thinking solve daily health issue application science technology engineering fall water corrective pen come poor family rysa aim shine spotlight importance mathematics stem subject workshop start playful way experio roche innovation science education uncover high standard equipment professional deep insight drug synthesis polymerase experiorochech researchbase healthcare company science young science talent hong kong supervision make experio roche unique chain reaction pcr gel electrophoresis technology core inception student switzerland allow schoolchildren try host basic technique apply research support year support multiple school participate different experiment supervision lab production line company community programme promote interest discipline specialist activity include programming robot open experio roche receive rochecom young people build foundation futurelab genentech science education solder electronic circuit understand visitor expect reach mark philanthropy science technology provide realworld science programme develop partnership chemical process involve drop ink visitor year skill enable continued education career south san francisco unify school district biotech hope help grow generation support science education grade level innovators elementary school high schoolimpacting student participate helix cup annual science competitionan integral genentech futurelab programme student south san francisco futurelab roche young scientist award hong kong support teachers professional development futurelab experio roche switzerland student field trip access scholarship lead example effort support classroom equipment supply young scientist globe teacher need curriculum give employee chance involve biannual roche young scientist award rysa volunteering mentoring launch partnership genentech employee volunteer hour programme offer exciting science experience local student student south san futurelab include creation science garage stateof theart biotech facility local francisco school benefit highschool student handson biotech class break ground september genentechs futurelab science education project highschool student participate biotech curriculum programme building complete roche community engagement community engagement roche sara shayesteh south san francisco unify school district futurelab mean world teacher love math science handson science eye opener educational career path clear graduated futurelab drive enthusiasm energy san francisco state university degree genentech employee care biology chemistry business work local community volunteer afterschool tutor research lab local biotech company work math science serve chaperone science interesting feel miss field trip assist classroom handson competition inspire student apply scientific finance college study partly tutor principle real world high school student math science enjoy connect see flash thank support genentech futurelab excitement eye understand difficult include college scholarship concept start parttime tutoring construction highschool biotechnology centre decidedafter soulsearchingto pursue call science garage open excited master degree education stanford university project opportunity roll new biotech curriculum science garage start work science teacher el camino high school south san francisco make difference student time unify school district student student story great example futurelab family live poverty impact family recent immigrant elementary student englishlanguage learner bright extremely interested sciencehe not excel science class young people natural scientist attend handson science field trip curious world way genentech opportunity science teach classroom today science come life everyday work successfully reach engage student learn transformative event bump english time know share s determined attend genentech invite join brainstorming college study computer science fact session focus improve science education enrol biotech class south san francisco hopeful possibility discussion emerge feel lucky futurelab witness futurelab programme positive impact student mean world teacher roche integrity business integrity business roche integ r ity material topic cover chapter drug efficacy safety counterfeit datum transparency clinical trial bu sine compliance disease awareness treatment education patient organisation support supply chain management biosimilar safety roche believe right thing mean good business s set high standard ethical contribution un sdgs behaviour live day critical supply chain portugal pharmaceutical warehousing partner rangel roche integrity business integrity business roche w e know integrity foundation business license operate key ability lasting impact public health compliance start lead example global compliance effort support senior executive act role model continually dedicated organisation lead chief compliance invite supplier work jointly improve supply chain sustainability reinforce importance compliance level officer affiliate network compliance company involve middle management vital function assist global function local line strong compliance culture management ensure necessary compliance develop middle management capability infrastructure place training standard transform supplier employee suggest improvement compliance leader ensure high ethical meet high level awareness sustainability audits assurance visit create innovation internal process service supplier code standard firmly embed daily work life compliance mutual benefit improve relationship create platform employee submit conduct believe employee roche supplier service provider idea eventually lead saving rochecom responsibility act integrity goal create atmosphere mutual trust supplier sustainability assurance visit worldwide company platform exist mannheim suppliercodeof systematic sustained approach anchor issue discuss openly employee direct spend area good directly penzberg germany rotkreuz basel conduct compliance culture compliance concern encourage speak production service provider switzerland site annual net saving different channel tolerate sixto sevendigit range psci foster global compliance culture retaliation employee raise collaborate supplier audits idea implement rotkreuz pscinitiativeorg code conduct guide roche employee concern good faith allegation investigate pharmaceutical company umbrella idea lead optimise release procedure reagent act integrity time employee complete substantiate corrective measure pharmaceutical supply chain initiative psci annual saving chf mannheim mandatory training ensure understand code sanction carry unified joint audit protocol focus latin production coagulation test streamline include voice compliance concern america engage supplier reduce lead annual saving eur business practice behaviour eg conflict interest sure supplier service provider environmental footprint average bribery improper advantage discrimination subject standard employee conduct joint risk assessment sole source harassment code express supplier code conduct include contract supplier mitigate identify risk expectation roche employee offer elearne programme help make supply resilient service compliance term patient safety product quality open supplier service provider understand provider relocate office close facility roche group code constructive dialogue stakeholder expectation industry standard provide well service employee roche group speakup line conduct code conduct applicable strict available language country chief rochecomcode local standard strongly believe compliance officer receive report relate alleged ofconduct consistent roche approach globe violation code conduct business ethic incident reporting system unfounded investigation substantiate result employment contract agreement business partner terminate ground unethical behaviour roche integrity business integrity business roche patient safety come arise country serialisation allow component patient management ivds regulatory authority distributor pharmacy rigorously validate analytically clinically continuously improve high standard physician trace verify time laboratorydevelope test ldts inhouse product handle roche test far subject regulatory supply chain serial number genuine oversight commercialise device test continue work health authority light concern safety efficacy voice patient general public stakeholder harmonisation ich guideline quality world share approach insight use ldts routine clinical place invaluable trust company management system inspect relevant health guarantee safety traceability interest decisionmake roche actively engage right expect roche medicine diagnostic authority worldwide internal quality patient stakeholder example public debate assessment product safe reliable high quality compliance audits regular basis ensuring invite hosted numerous meeting delegation ldts new regulatory framework available compliance good manufacturing practice health authority educate train inspection conduct regulatory product security meeting share good practice animal testing meet expectation enforce authority worldwide demonstrate commitment patient safety clinical trial new medication standard operational performance include serialisation traceability technique conduct human regulatory body worldwide constant review ongoing improvement pharmaceutical production facility shanghai beneficial wide health community require efficacy safety datum base animal quality standard precision clarity china illustrate dedication quality testing regulation allow packaging product information site successfully pass regulatory aligning biosimilar guideline global standard scientifically possible ethical roche employ monitor link international supply audits health authority world world health organisation medical testing procedure require chain addition continue strengthen shanghai site helps meet grow publish guideline define evidence require animal switzerland support r research business continuity management ensure pharmaceutical need china production biotherapeutic product consider foundation provide fund research site affiliate strategy tactic place hub part world biosimilar recommendation outline project promote rs replace animal test deliver minimum level vital product service guideline build national possible reduce number animal enhance safety quality serialisation biosimilar regulatory process study refine exist practice roche actively ensure patient safety mean collaborate patient complete confidence roche country world order ensure engaged discussion future continuously regulatory agency carefully check medicine authentic highquality product patient safety roche believe local regulatory foundation lead federal food safety report adverse event experience patient problem counterfeit adulterate pathway relate biosimilar align veterinary office consideration give communicate transparently regularly drug exist decade risk increase global standard set roche respect establish national r competence centre product quality roche safety risk management dramatically recent year internet sale legitimate undertaking competitor include department systematically monitor roche drug difficulttocontrol source generic biosimilar manufacturer expect play lead role share good practice worldwidebefore launch adverse comply applicable law regulation animal testing china example key opinion event record global database review roche implement initiative improve industry code protect product leader representative contract research report promptly appropriate regulatory exist regulatory requirement help create interest unfair competition organisation invite roche authority require employee report drug new standard product safety security quality innovation center shanghai discuss stateof safety quality issue immediately complete way enhance safety quality rigorously validate diagnostic test theart practice participant sign china animal animal study annual awareness train adverse event report medicine serialisation understand world leader vitro diagnostic ivd welfare nonclinical quality charter go rochecomanimal labelling single package unique serial roche develop diagnostic test critical current local regulatory requirement welfare medicine meet high quality standard number standard start time roche pharmaceutical quality system roll safety feature numerous country process comply international conference supportive new serialisation regulation roche integrity business integrity business roche matter engagement engage government official industry benefit datasharing come life body contribute public debate work clinical development plan antibiotic earning stakeholder trust development effective public health law need specific datum advance development regulation policy datum transparency policy adopt european medicine agency roche receive datum enhance access healthcare week year european patient forum epf highly take datum transparency essential earn trust stakeholder contribution patient organisation regard voice urge politician reinforce euwide build understand concern truly total chf million collaboration access new medicine roche strive clinical study information embed daily business able make significant contribution new access available patient physician researcher jointly develop solution annual sustainability reimbursement model eu support subject protection patient privacy forum bring internal stakeholder financial contribution patient organisation shift traditional approach pricing medicine commercial confidentiality collaborate external expert discuss innovation nonfinancial contribution patient organisation pack vial multipleindication pricing range organisation wellcome trust enhancement commitment engagement service contract patient organisation outcomebase approach advocate transcelerate involve advance develop key performance indicator kpi development datum infrastructure implement opportunity datasharing measure monitoring progress area dedicate engage transparent dialogue approach relevant stakeholder healthcare professional nature introduce update version roche collaboration include support attend important center medicare medicaid policy sharing clinical information document foster transparency relationship congresse conference field comply service cms federal agency charge reflect change regulatory environment patient organisation healthcare professional disclosure requirement example implement innovative payment delivery encourage great understanding approach patient organisation key partner sunshine act efpia disclosure code model healthcare system decrease cost belief value datasharing provide provide forum patient caregiver share adapt disclosure guideline improve enhance quality care cms currently overview guide principle story experience help shape internal external transparency testing model include accountable care detail information available current future healthcare environment organisation bundle payment oncology care channel use make collective voice hear help contribution healthcare organisation model medicare b drug payment model understand human experience personal total chf million model aim transition traditional engage political institution challenge disease provide invaluable feeforservice valuebase payment roche remain independent political affiliation nonfinancial insight improve product development genentech active discussion support number association report clinical trial programme research commercial public payer role political institution switzerland spend rochecomnon education healthcare professional certain innovative payment model play chf million include payment financialreporte support patient organisation base education patientsgeneral public healthcare reform industry association chamber write agreement state purpose support healthcare infrastructure commerce financial assistance trade union working financial support significant support personalise healthcare share datum advance scientific progress donation political party cantonal patient group indirect nonfinancial benefit accordance patient screening share clinical information understand federal level donation political party rochecom industry guideline detail help physicians patient healthcare provider lowdoubledigit thousand range swiss franc patientorganisation relationship patient organisation public informed treatment decision enable account total researcher advance scientific progress see contribution donation roche integrity business integrity business roche eduardo rangel rangel logistics solution special task base share commitment learn value hard work early life shake hand start intensive period age trainee custom office collaboration rangel invest heavily new porto study administration accounting warehouse cold chamber transportation night year name head box remain constant degree celsius export department roche quality expert come site lisbon train people know teamwork base aged take bold decision start share commitment lifesave product freightforwarde company hospital pharmacy patient need colleague tough find investor customer convince people willingness january go live soon long hour determination succeed introduce track trace website engineer create programme roche follow shipment monitor process custom declaration electronicallywe realtime temperature delivery truck company portugal offer software big challenge come look proud keep creation european union phase promise miss custom duty europe eliminate single delivery fail cold chain business reinvent expand fulfilment rate internationally open new market today rangel successful international group partnership base trust employee learn october meet adriano treve general collaboration roche number manager roche portugal time need distributor pharmaceutical product portugal distributor transport sensitive oncology product supply million lifesaving product year completely honest tell experience pharmaceutical willing chairman training son nuno invest learn trust retire great wish ask look eye reply rangel group family continue fulfil put reputation reputation promise future company line promise roche corporate governance corporate governance roche cor porate gove r nance roche corporate governance corporate governance roche principle board director roche commit serve stakeholder corporate governance requirement particular th annual general meeting agm board director corporate executive basis successful implementation applicable law swiss stock exchange roche holding ltd march shareholders committee commitment corporate governance principle swiss exchange directive swiss code reelect dr christoph franz chairman accordingly focus business activity good practice corporate governance promulgate board director march forthcoming agm board sustainable value creation innovation prescribe swiss business federation economiesuisse director nominate chairman remain management culture conform recognise company internal governance framework particularly furthermore agm reelect andr hoffmann members board director reelection standard good corporate governance policy article incorporation bylaw embody prof dr pius baschera prof sir john bell paul bulcke transparent communication principle need ensure company prof dr richard p lifton dr andreas oeri prof dr pius baschera member business manage supervise manner bernard poussot dr severin schwan peter r voser board director decide stand strong board director represent consistent good corporate governance include elect julie brown dr claudia sssmuth reelection announce december interest shareholder stakeholder necessary check balances dyckerhoff new member board director highly skilled manager act integrity term year provide article board nominate anita hauser election new extremely important print annual report contain select link incorporation dame deanne julius member board director agm roche website wwwrochecom reader prof dr beatrice weder di mauro stand th consecutive year roche provide snapshot company reelection board director nominate recognise dow jones sustainability indices report date direct source dr christoph franz andr hoffmann group leader sustainability consult time uptodate addition agm elect dr christoph franz prof dr richard p lifton bernard poussot pharmaceutical biotechnology life science information corporate governance roche andr hoffmann prof dr richard p lifton peter r voser reelection member industry sustainability core business annual report cover single financial bernard poussot peter r voser member remuneration committee agm practice award reflect commitment year end december website contain remuneration committee run business way ethical information permanent nature previous year board director responsible create longterm value stakeholder late roche news company article organise meeting immediately follow nominates bdo ag independent proxy incorporation bylaw curricula vitae agm board director determine period conclusion corporate governance report set member board director corporate structure composition remain committee ordinary annual general meeting shareholder structure process rule roche take executive committee publish website show page election agm basis wellfunctione corporate governance roche complie relevant detail refer follow report composition year birth elect board director dr christoph franz c e chairman andr hoffmann representative c e vicechairman annual general meeting annual general meeting shareholder group pool voting right dr andreas oeri representative e board director shareholder group pool voting right prof dr pius baschera e board director board committees prof sir john irving bell b e julie brown b e presidium nomination committee board committees paul bulcke b e remuneration committee prof dr richard p lifton c e audit committee bernard poussot c e corporate governance sustainability committee dr severin schwan f dr claudia sssmuth dyckerhoff b e corporate executive corporate executive committee peter r voser c e ceo ceo general committee ceo cfo hr secretary dr gottlieb keller pharmaceutical diagnostic counsel board director enlarge corporate executive committee honorary chairman dr fritz gerber enlarge corporate gred pre partnering communication board director executive committee chugai corporate governance sustainability committee b audit committee c remuneration committee presidiumnomination committee e nonexecutive director f executive director committee chairperson rochecomgovernance roche corporate governance corporate governance roche corporate executive committee group structure shareholder silvia ayyoubi head group human resource membership corporate executive roche operate business organise note financial statement roche roche member corporate executive committee remain unchanged division pharmaceutical diagnostic hold ltd significant shareholder committee retire roche march pharmaceutical division comprise business addition significant shareholder publish exchange board director appoint cristina wilbur information member corporate segment roche pharmaceutical chugai relevant webpage disclosure office regulation succeed silvia ayyoubi head group human executive committee enlarge corporate genentech segment exchange regulation sixexchange resource member corporate executive executive committee list page integrate roche pharmaceutical diagnostic regulationcom committee board director corporate division consist follow business area andr hoffmann vicechairman board significant executive committee diabetes care molecular diagnostic professional director chairman remuneration shareholder diagnostic tissue diagnostic committee dr andreas oeri member board director chairman board composition year birth position business activity carry group corporate governance sustainability committee corporate executive dr severin schwan ceo roche group subsidiary associate company detail serve respective capacity board committee daniel oday ceo roche pharmaceutical information roche holding ltd significant committee representative shareholder roland diggelmann ceo roche diagnostic subsidiary associate company include group pool voting right receive dr alan hippe chief financial officer company list information domicile share remuneration set forth remuneration report cristina wilbur head group human resource capital equity interest list finance finance report note dr gottlieb keller general counsel report note roche group consolidated roche group consolidated financial statement enlarge corporate osamu nagayama chairman ceo chugai financial statement subsidiary associate relate party exception executive committee dr michael varney head genentech research dr jrg duschmal work postdoc roche early development gre relationship exist shareholder prof dr john c reed head roche pharma research major shareholder list finance report pool voting right early development pre note roche group consolidated dr stephan feldhaus head group communication financial statement equity attributable roche crossshareholding dr sophie kornowskibonnet head roche partnering shareholder relate party page secretary corporate perolof attinger executive committee statutory auditor kpmg klynveld peat marwick goerdeler sa reporting year roche holding ltd kpmg ag auditor charge john morris roche pharmaceutical incl genentech pharmaceutical ian starkey chugai chief compliance officer dr urs jaisli professional diagnostic molecular diagnostic diagnostic tissue diagnostic diabetes care composition corporate executive corporate executive committee ceo ceo general committee ceo cfo hr pharmaceutical diagnostic counsel enlarge corporate executive committee enlarge corporate gred pre partnering communication executive committee chugai roche corporate governance corporate governance roche capital structure board director corporate executive committee information roche capital structure provide include provision protect interest finance report note financial statement nes holder describe article roche holding ltd additional detail incorporation roche holding ltd information member board director capacity group subsidiary contain article incorporation roche member corporate executive financial year preceede current reporting holding ltd information debt instrument committee list page member period lack exist business issue outstanding bond provide board director age limit restriction connection group subsidiary independent movement recognise amount finance report note roche group term office curriculum vitae current independence definition base definition financial year detailed finance consolidate financial statement debt member year swiss code good practice corporate report note financial statement roche body information include information governance economiesuisse holding ltd information employee stock option provide year election board member finance report note roche group additional position membership activity principle governance principle delegation company share capital chf consolidated financial statement equity available continuously update internet competence reservation power management divide fully pay bearer share compensation plan include detailed group company executive body nominal value chf information stocksettle stock appreciation rule pursuant article para point vegv company include economic environmental restriction exercise vote right right ssar plan roche restrict stock number permit activity board social topic principle internal share deposit share vote unit plan roche performance share plan director corporate executive committee organisation board director division restriction roche connect roche option plan member outline article authority responsibility board incorporation roche holding ltd management remits board committee authorise conditional capital roche issue option apart employee information control mechanism available stock option describe finance report annual general meeting elect board dealing corporate management addition nonvoting equity security note roche group consolidated financial member board director chairman govern bylaw nes issue bearer form statement equity compensation plan board director member form share capital confer voting option issue connection debt instrument remuneration committee annual basis board director roche holding ltd right ne confer right election nominee vote separately organise ensure group conduct share participate available earning option award employee article incorporation roche business responsibly focus longterm liquidation proceed follow repayment share debt instrument issue hold ltd minute th annual value creation end roche board capital roche nes right pertain thereto effect roche share capital general meeting roche holding ltd hold delegate certain responsibility committee march composition chairperson december describe committee exception dr severin schwan authority responsibilitie define detail member board director office bylaw board director end member roches corporate executive committee serve executive committee chair independent director board director board director board committee presidium nomination committee board committee rochecomarticleofincorporation remuneration committee rochecomboardofdirector rochecomexecutivecommittee audit committee rochecomarticleofincorporation corporate governance sustainability committee rochecomannualgeneralmeeting rochecomarticleofincorporation corporate executive corporate executive committee rochecomcommittee committee rochecomarticleofincorporation roche corporate governance corporate governance roche accord bylaw board director auditor finding present audit safety health environmental protection board director meet meeting board meeting convene chairman committee board department generally hour length include present request member roche detail risk management include risk corporate sustainability committee fullday meeting addition day visit board meet year assess chairman factor risk management policy science ethic advisory group seag major subsidiary board committee meet performance meeting attend risk management website financial risk issue relate genetic genetic engineering follow chairman chair vicechairman management specifically describe presidium board directorsnomination finance report member corporate executive committee committee meeting approx hour management information system mis system internal control financial reporting invite attend meeting board remuneration committee meeting approx board director inform page finance report director report person agenda hour important issue sale performance etc monthly internal audit item concern situation warrant audit committee meeting approx hour basis board access electronic information group audit report general counsel member enlarge corporate executive platform provide timely information direct access give regular briefing audit committee invite attend board corporate governance sustainability board director board committee committee corporate governance committee invite chairman board committee meeting approx hour system control set forth sustainability committee ongoing activity corporate executive committee member deliver audit report chief audit risk advisory report committee meeting elect board director regularly conduct board director establish system executive attend audit committee partly commission independent expert report assessment selfassessmentassessment party control continuously monitor corporate governance sustainability service consultant electronical survey personal interview audit committee corporate governance committee meeting external auditor performance selfassessment board sustainability committee board year blackout period impose director conduct director consist follow element group audit independent appraisal function senior employee prohibit report operate financial risk risk evaluate review group activity trade company stock follow blackout member corporate executive committee management system service management annual audit plan period effect maximum ordinary notice period month roche group establish risk management yearly define focus area eg market access december february changeofcontrol clause process cover entire company system party management validate senior management april april employment contract place identify manage type risk present audit committee roche june july potentially affect business include economic group commit maintain high standard october october management contract fall environmental social impact risk internal control worldwide operation blackout period change chairman scope subsection annex directive opportunity contain stakeholder input management responsible assess board director circumstance warrant information relate corporate governance board director high governance business risk aspect operation body involve roche risk management policy set implement effective efficient process approach accompany responsibility control whilst ensure compliance internal pharmaceutical diagnostic division external rule regulation global function conduct formal risk assessment conduct operational audits group audit process year develop risk determine management response risk plan material risk surround business process system monitor deviation review regular evaluate appropriateness completeness performance dialogue consolidate group risk efficiency process control action plan report include target risk profile discuss implement necessary change enhancement corporate executive committee approve develop businessauditee group business plan material track completion risk review board yearly basis statutory auditor effectiveness risk management process chief compliance officer compliance officer monitor group risk advisory team subsidiary overall process regularly review external rochecomriskmanagement rochecomenvironment additional information provide finance report note roche group consolidate financial statement risk management rochecomsustainability rochecomethicalconflict remuneration committee member recuse deliberation decision matter affect interest figure indicate actual length meeting include director extensive premeete preparation postmeete followup activity roche corporate governance corporate governance roche remuneration shareholding loan board board committee attendance corporate presidium governance rule aol nomination remuneration audit sustainability detail remuneration shareholding board committee committee committee committee loan content method determine content board cec number meetings compensation shareholding programme rule principle ch franz basic principle element compensation applicable performance hoffmann shareholding programme serve related pay p baschera member board director corporate rule principle j bell executive committee description allocation equity securities j brown march authority procedure determine convertible right option p bulcke set forth separate remuneration report additional payment rp lifton page finance report note member executive b poussot roche group consolidated financial committee appoint schwan statement equity attributable roche shareholder vote pay general oeri related party page list meeting shareholder c sssmuth dyckerhoff note financial statement roche rule loan credit facility march holding ltd board executive shareholding postemployment benefit p r voser rule vote pay retire board member agm retire march follow rule remuneration shareholding julius loan board director board b weder di mauro corporate executive committee cec set forth article incorporation aoi member committee invite guest board committee meeting participatory right shareholder dr andreas oeri chairman corporate governance sustainability committee participatory right shareholder article incorporation define roche article incorporation shareholder represent share nominal roche share issue bearer value chf million request restriction admission annual general placement item agenda annual meeting exception share general meeting later deposit specify period date day date meeting meeting admittance card issue shareholder provide rule issue instruction article incorporation shareholder elect independent proxy rule electronic represent party annual participation agm lay general meeting correspond invitation agm regulate article incorporation article incorporation contain restriction exercise voting right quorum requirement stipulate conformity swiss code obligation rochecomarticleofincorporation roche corporate governance corporate governance roche change control defensive measure statutory auditor elect year service include advice relate process annual general meeting improvement regulation training article incorporation contain provision terminate event acquisition auditing service provide legally require company formal policy govern mandatory bid rule swiss law apply vest period restriction preexist award engagement statutory auditor nonaudit remove option auditrelated service include assurance service policy prohibit certain service changeofcontrol clause exercise immediately accounting service provide auditor provide permit certain service component remuneration base roche ne necessarily provide statutory auditor limit agree audit committee service include audits pension fund potential nonaudit service engagement review employee benefit plan internal control review policy authority proceed legal requirement give attestation service comfort letter consent relationship statutory auditor consultation tax service include service respect compliance tax return tax advice annual general meeting roche holding ltd report statutory auditor consolidated services relate audit tax march shareholder vote appoint financial statement financial statement kpmg ag kpmg statutory auditor base find page respectively exist legal requirement swiss code year finance report obligation article concern maximum relationship independent proxy term office seven year auditor charge kpmg receive follow remuneration ian starkey replace predecessor john morris services statutory auditor roche holding ltd auditorincharge start business year auditor roche company information long auditor auditorin include chugai recent year bdo ag serve independent rule issue instruction charge serve capacity provide proxy annual general meeting independent proxy rule electronic statutory auditor participate march shareholder elect bdo ag participation agm lay audit committee meeting prepare write millions chf independent proxy period correspond invitation agm oral report result audits audit auditing service conclusion ordinary annual general regulate article incorporation committee oversee assess auditor auditrelated service meeting shareholder bdo ag pay make recommendation board information assurance service accord expenditure totalling authority responsibility audit non statutory audits chf chf committee article bylaw tax service statutory auditor participate meeting service audit committee total rochecomarticleofincorporation roche corporate governance corporate governance roche information policy chief compliance officer compliance officer network provide article incorporation relevant information document include corporate notice publish swiss official medium release investor update presentation gazette commerce daily newspaper analyst investor conference available chief compliance officer compliance furthermore serve platform idea designate board director basler zeitung internet publication available officer network commit ensure suggestion concern document finanz und wirtschaft lagefi le temps neue rochecompublication order roche group code conduct consistently zrcher zeitung email fax comply roche group addition roche establish business ethic baselwarehouseservicesrochecom serve contact person shareholder employee incident report beir system enable roche report halfyear fullyear result fax customer supplier general public issue chief compliance officer capture track business report publish print andor online relate implementation compliance monitor allege violation initial report format medium event addition detailed contact address investor relation code employee party local compliance officer resolution firstquarter month sale figure fhoffmannla roche ltd investor relation aware violation roche group code publish year april october group finance basel switzerland conduct bring attention business ethic incident record system current list publication date available tel manager supervisor local compliance local management receive specific english german internet fax officer report chief compliance officer concrete information allege violation dr urs jaisli direct phone number roche group code conduct certain pre additional information include detail specific email ursjaislirochecom disclosure define category corporate governance contact person available internet treat confidentially addition end sustainability committee audit committee employee anonymously report irregularity board director inform substantial complaint mother tongue speakup violation management corrective action line start december new compliance tool group level socalle roche group code chief compliance officer report general conduct help advice line introduce counsel submit regular report strives provide guidance case question corporate governance sustainability committee uncertaintie interpretation roche need audit committee board group code conduct reference document director nonapplicabilitynegative disclosure expressly note information contain provide swiss exchange corporate mention nonapplicable governance directive commentary thereto omission construe negative declaration rochecomarticleofincorporation rochecommedia rochecominvestor rochecominvestorscontact rochecomcodeofconduct rochecomriskmanagement roche remuneration report remuneration report roche mune ration por material topic cover chapter executive compensation roche remuneration report remuneration report roche principle remuneration decision process approval framework roche success depend substantially expertise global company like roche marketcompetitive motivation performance employee remuneration play key role performance conviction form basis compensation policy base transparent compensation structure ensure overview power procedure make remuneration compensation package competitive year remuneration committee roche decision find bylaw roche aim remunerate employee fairly structure individual component regularly board director decide remuneration roche board director article transparently line market condition benchmarke swiss european international board member member group incorporation outline enable participate appropriately criteria remuneration guideline corporate executive committee term section principle govern specific company success pursue goal provide underlying principle subject regular longterm orient performance share plan psp remuneration component competitive performancebased resultsoriente outside comparison award decide annually board compensation director act recommendation total aggregate amount base compensation policy factor remuneration committee decision submit general strive balanced mix fix variable safeguard roche future success key meeting approval implement ordinance compensation component gear employee element corporate culture offer employee remuneration committee track market datum excessive compensation list corporation position management responsibility condition good possible salary lead global pharmaceutical verordnung gegen bermssige vergtungen bei contribution share corporate goal improve company major swiss company brsenkotierten aktiengesellschaften vegv firstly variable component intend create healthcare patient include sound value report finding board external general meeting shall vote annually bind additional financial incentive achieve corporate system base integrity courage passion consulting firm pricewaterhousecooper pwc effect approval remuneration goal innovation consistently high time decentralise management assist remuneration committee roche board director resolve board compensation level increase value company approach play major role wide scope perform market comparison advise director corporate executive committee policy create stakeholder group secondly order individual decisionmake respectful interaction information remuneration committee remit detail rochecomreward allow employee manager participate openness diversity widerange training company business success adequate compensation development opportunity attractive work sound value system measure key objective incentivise environment unidimensional diminishment remuneration decision process approval framework rochecomlive annual bonus payment longterm sharebase question remuneration fall far short beneficiary ourvalue programme remuneration board director bod corporate executive decision approval roche commit fair performancebase component chairman c committee cec incl ceo roche group resultsoriente compensation policy link employee interest base payremuneration stakeholder group bonus c stocksettle stock appreciation right remuneration committee restrict stock unit cec annual general replace award meeting correspond psp performance share plan board director recommendation remuneration committee decision pension c remuneration committee peer set abbott laboratories abbvie amgen astella astrazeneca bayer bristolmyers squibb eli lilly glaxosmithkline johnson johnson merck co novartis pfizer sanofi takeda change composition peer set compare abb actelion credit suisse lafargeholcim nestl sonova straumann swis ubs zurich insurance rochecomarticleofincorporation rochecomarticleofincorporation roche remuneration report remuneration report roche peer set procedure submit total board retrospective approval executive remuneration shareholder approval total aggregate bonus amount corporate abbott laboratory abb annual general meeting executive committee chairman board abbvie actelion year annual general meeting agm director financial year end amgen credit suisse shareholder approve total remuneration submit retrospectively ordinary agm astellas lafargeholcim board director corporate executive separate bind approval astrazeneca nestl committee decide board director roche bayer sonova remuneration committee board director prospective approval bristolmyer squibb straumann respectively board executive aggregate remuneration eli lilly swiss submit prospectively agm separate glaxosmithkline ubs accord approval agm bind approval period johnson johnson zurich insurance roche commit obtain separate ordinary agms merck co bind shareholder approval total peer set novartis remuneration pay board director pfizer corporate executive committee follow sanofi takeda market comparison company salary assessment approval total remuneration annual general financial year financial year meeting pharma peer set major swiss company retrospective chairman bod c c bonus financial year total bonus corporate executive committee cec include ceo roche group cec bonus andr hoffmann chairman remuneration committee bonus financial year total prospective board director bod include c bod base payremuneration aggregate total remuneration agm agm base payremuneration corporate executive committee cec include cec ceo roche group base pay aggregate total remuneration agm agm ssar psp base pay indirect benefit stocksettle stock appreciation right ssar performance share plan psp indirect benefit agm agm agm roche remuneration report remuneration report roche remuneration component variable sti base salary bonus overview remuneration element remuneration component link indirect benefit employer contribution remuneration member board employee performance company financial lti pension insurance contribution director corporate executive committee performance commercial success align stocksettle stock roche connect compose follow element concrete interest roche employee appreciation right roche tax consulting service composition chart composition shareholder performance share plan remuneration remuneration board director expense allowance corporate executive committee lti remuneration component intend component sustainably homogenously longterm orient children school cost fix base salary complement align management interest shareholder foreign tax obligation annual variable bonus shortterm incentive sti holder nonvoting equity security ahvivalv perennial variable remuneration element participate manager additional incentive ssar psp longterm incentive lti achieve value growth form longterm total fix shareholder return create value roche restrict stock unit rsus remuneration investor management benefit component corporate executive committee add longterm value create investor replace award correspond psp management penalise receive base pay fix individual performance objective member base pay cash payment determine corporate executive committee position base salary market datum lead composition remuneration board director corporate executive committee global pharmaceutical company footnote december end report year major swiss company footnote january follow report year remuneration annual remuneration element description c bod ceo roche group cec reflect individual ability experience committee decide bonus amount base pay monthly payment quarterly performance time pay adjustment likewise payable chairman board member remuneration payment link individual performance corporate executive committee respect bonus annual payment year year cash account prevail market condition current reporting year base performance block share block share company overall financial situation aforementioned objective pension etc time remuneration committee decide perennial remuneration committee make review form bonus award ie cash payment remuneration element final decision individual base pay pay andor longterm block nonvoting equity security stocksettle stock chairman board director members andor block share appreciation right corporate executive committee ssar remuneration member board stocksettle stock appreciation right performance share year variable plan psp block share bonus variable ssar entitle holder benefit financially bonus annually award individual increase value roche nonvoting equity contribution value creation business year security grant date exercise date mean incentive strive outstanding ssar grant vest result create new business opportunity year exercise seven year bonus amount link group divisional grant date unexercised ssar lapse core profit sale growth constant exchange rate compensation fair value ssar operate profit capital charge opac base calculated grant date trinomial core operating profit core earning share model american option detail nonvoting equity security ne growth constant exchange rate product development pipeline ssar awards corporate executive committee achievement measurable qualitative allocate individually remuneration individual functional performance objective committee discretion addition competitive reason roche disclose employee receive ssar awards roche remuneration report remuneration report roche restrict stock unit variable finishing end year indirect benefit foundation supplement occupational pension restrict stock unit rsus contain right overlap performance cycle psp show ceo roche group benefit insurance roche connect receive nonvoting equity security andor share psp psp chairman respectively member payment foreign tax obligation tax threeyear vest period plus value psp close december corporate executive committee additionally consult service annual expense allowance adjustment equivalent psp cycle target ne receive indirect benefit payment pension show individual member sum dividend pay vest period award psp december fund mgb stiftung der f hoffmannla roche ag corporate executive committee receive payment attributable number nonvoting equity target ne award psp fr mitarbeitergewinnbeteiligung al ergnzung schooling cost child security individual award december target nes der beruflichen vorsorge ie employee profitsharing grant rsu award allocate individually award remuneration committee discretion weight fixedvariable remuneration component target percentage total remuneration vest recipient year plan key performance metric award result nonvoting equity security total shareholder return tsr calculate remain block year threemonth move average rate start chairman vest block period interest end performance cycle rsu recipient shall align company payment performance share plan determine board director longterm success commitment employee board director annual basis act corporate executive company shall increase recommendation remuneration committee include ceo committee roche group rsus remuneration component corporate executive committee replace start psp award remuneration award correspond psp component reserve corporate executive fix variable variable longterm incentive programmes committee enlarge corporate executive corporate executive committee comprise psp committee whilst previous year member ratio variable remuneration component relative fix base pay corporate executive award ssar approximately senior management participate performance committee share plan structure lti simplify ratio variable remuneration component bonus ssar psp relative value fix base pay comparison competitor company long longterm incentive programme term performance mirror share previous psp participant comprise sti lti price total shareholder return tsr shall ssar rsus award approximately criteria bonus ssar psp stronger reflect corporate executive individual target value committee remuneration minimum psp historical performance maximum rsus remuneration component continue award originally target ne performance criterion group objective group divisional value development value development authorised roche business performance individual determined performance determine performance employee objective consider core profit sale plus value adjustment plus value adjustment growth constant exchange rate dividend ne dividend nesbearer performance share plan psp variable operating profit capital charge opac grant share grant psp establish period base core operating profit core earning group performance tsr year base threeyear comparison share nonvoting equidity security relation tsr performance tsr peer company footnote nes growth constant exchange rate peer set tsr definition product development pipeline respective year psp consist split overlap performance cycle new cycle group objective na starting begin year cycle b individual objective na na applicable assess consideration performance competitor macroeconomic development base annual base pay measure january year cycle detail refer follow section remuneration report finance report note roche group consolidate financial statement relate party note financial statement roche holding ltd board executive shareholding roche remuneration report remuneration report roche remuneration board director resolution approval remuneration member remuneration chairman board board director director member board director member board director decide remuneration committee receive remuneration additional compensation discretion take account market comparison form quarterly fix cash payment show remuneration member board remuneration form cash payment director table board annually track market datum director activity roche pay legally require employer pay lead global pharmaceutical contribution total chf swiss social company footnote major swiss security programme provide retirement disability company footnote assist unemployment benefit ahvivalv consultancy pwc member board director legally require contribution separately state previous year board chairman board director director separately submit total aggregate bonus chairman board director basic remuneration board director general meet financial year exclude chairman remain unchanged retrospectively bind approval maximum amount total aggregate exception chairman board remuneration board director period director bonus form block share ordinary general meeting dr severin schwan executive member ordinary general meeting table board member board director previous year general meeting award share nonvoting equity security prospectively bind approval ssar loan credit grant member board director capacity member chugai international council cic chugai pharmaceutical co ltd andr hoffmann receive honoraria amount total usd chf list member position committee membership chairmanship detidua remuneration member board director chf additional compensation additional special basic remuneration committee memberschair compensation total remuneration ch franz chairman total remuneration pay chairman board directors ahoffmann vicechairman pbaschera jbell jbrown march pbulcke rp lifton aoeri bpoussot sschwan high total remuneration pay dr severin schwan member corporate executive committee remuneration receive primary function ceo roche group reflect total remuneration corporate executive committee csssmuth dyckerhoff march pr voser djulius retire march bweder di mauro retire march total exception member presidium chairman vicechairman board member receive chf year committee serve chf year committee chair remuneration serve vicechairman board prorate remuneration period march december prorate remuneration pay period january march additionally employer contribution ahvivalv totalling chf include chairman pay form compensation detiduaroche remuneration report remuneration report roche detidua total remuneration pay chairman form bearer share block year payable board director april shareholder bind vote chairman dr christoph franz receive total ordinary annual general meeting agm remuneration show remuneration committee bonus proposal adopt chairman total remuneration contain late respect financial year total remuneration board director total remuneration pay chairman board director chf base salary cash bonus subject approval annual general meeting pension fundsmgb insurancesannual expense allowance total form share block year calculation number share base share price date transfer april respectively approval agm agm respectively calculation value consideration reduction value block period year reduce market value submit shareholder approval agm approve agm respectively nclude employer contribution social security beneficial part gb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit additionally employer contribution ahvivalv chf pay form compensation detidua total remuneration pay board board remuneration subject approval director annual general meeting calendar year member board director receive remuneration include bonus submission chairman total aggregate totalling chf chf bonus bind vote annual general exclude additional employer contribution pay meeting ahvivalv totalling chf remuneration chairman board chf form compensation director include bonus award chf form share block year show remuneration pay member table total remuneration pay chairman board director board director board member board director dr franz director submit remuneration committee bhumer receive honoraria amount bonus proposal adopt late chairman total usd chf serve board dr christoph franz respect member board director member financial year payable april exclude chugai international council cic chugai legally require employer contribution ahviv pharmaceutical co ltd alv shareholder bind vote ordinary annual general meeting agm member board director william burns receive honoraria amount total usd chf capacity member chugai international council cic chugai pharmaceutical co ltd additional remuneration pay detidua remuneration member board director chf additional compensation additional special basic remuneration committee memberschair compensation total remuneration ch franz chairman total remuneration pay chairman board directors ahoffmann vicechairman pbaschera jbell pbulcke djulius rp lifton aoeri bpoussot sschwan high total remuneration pay dr severin schwan member corporate executive committee remuneration receive primary function ceo roche group reflect total remuneration corporate executive committee pr voser bweder di mauro total exception member presidium chairman vicechairman board member receive chf year committee serve chf year committee chair remuneration serve vicechairman board prorate remuneration period march december additionally employer contribution ahvivalv totalling chf include chairman pay form compensation retrospective approval chairman total aggregate bonus chf proposal agm agm agm aggregate aggregate aggregate financial year financial year financial year total aggregate proposal approval approve agm exclude legally require employer contribution ahvivalv bonus award form share block year calculation number share base share price date transfer april april respectively approval agm agm respectively calculation value consideration reduction value block period year reduce market value submit shareholder approval agm approve agm respectively include dr franz b humer bonus chairman submission board total aggregate dr severin schwans remuneration show future remuneration bind shareholder vote receive function ceo roche board director propose group member corporate executive ordinary agm approve board remuneration totalling committee include chf exclude legally corporate executive committee total remuneration require employer contribution ahvivalv exclude bonus period end ordinary agmroche remuneration report remuneration report roche prospective approval board total aggregate future remuneration chf security holding share ne proposal agm agm agm december december aggregate aggregate aggregate close relative close relative security security period period period share ne holding share ne holding agm agm agm agm agm agm number number numbertype number number number numbertype number total aggregate proposal approval board director approve agm ch franz hoffmann exclude legally require employer contribution ahvivalv exclude bonus p baschera j bell j brown na na na na reconciliation report remuneration comparison ordinary agm p bulcke shareholder approve remuneration ordinary agm actual remuneration amount rp lifton member board director chf exclude legally require employer oeri ordinary agm approve board remuneration contribution ahvivalv exclude bonus b poussot totalling chf exclude schwan security holding security holding legally require employer contribution ahviv corporate executive committee corporate executive committee alv exclude bonus period end c sssmuth dyckerhoff na na na na ordinary agm pr voser retire board member prospectively approve total remuneration member board director comparison actual total retire march payment chf julius na na na na b weder di mauro na na na na total remuneration total remuneration total remuneration period period period total agm agm agm agm agm agm na applicable maximum total remuneration approve agm share hold shareholder group pool voting right list actual total remuneration pay calculation end period jointly hold close relative approve limit calculation end period yes yes exclude legally require employer contribution ahvivalv exclude bonus security holding statement related party note director andr hoffmann dr andreas oeri financial statement roche holding ltd member founder family significant shareholder addition closely associate belong contractually december december bind shareholder group pool voting right respectively member board director end group hold share person closely associate hold share issue share detailed information nonvoting equity security nes show group find finance report table security holding note roche group consolidate financial roche remuneration report remuneration report roche remuneration corporate high total remuneration pay dr severin schwan member corporate executive committee chf executive committee base salary ssar resolution approval remuneration committee board rsus restrict stock unit remuneration member corporate director outline page remuneration pension fundsmgb insurance executive committee decide decision process approval framework roche connect remuneration committee discretion take subtotal account market comparison member corporate executive bonus subject approval total aggregate bonus corporate executive committee committee receive remuneration work annual general meeting previous year board director show remuneration block nonvoting equity securitiesshare separately submit total aggregate bonus ceo roche group dr severin schwan psp corporate executive committee general explain detail payment expense allowancefor tax consulting service meet financial year retrospectively total bind approval high total remuneration pay dr severin c alculation value nonvoting equity securitiesshare consideration reduction value block period year reduce market schwan member corporate executive value maximum amount total aggregate committee include employer contribution social security beneficial part detailed calculation remuneration annual report remuneration corporate executive committee dr severin schwan executive member board number ssar grant value accord trinomial model american option chf trinomial model american period ordinary general meeting director receive remuneration primary option value describe stocksettle stock appreciation right ssar member corporate executive committee ordinary general meeting function ceo roche group reflect number ssar grant value accord trinomial model american option chf trinomial model american table previous year general high total remuneration pay member option value describe stocksettle stock appreciation right ssar member corporate executive committee meeting prospectively bind approval corporate executive committee member corporate executive committee receive rsus anymore replace award correspond psp include total pay corporate number rsus grant value chf ne closing price grant date march rsu gb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational remuneration member executive committee total remuneration pension benefit corporate executive committee pay member corporate executive share block year calculation number share base share price date transfer april approval agm general provision assign authority decision committee target number bearer share psp bearer share multiply bearer share price average month october corporate executive committee remuneration december prior start performance cycle chf bearer share target number bearer share psp bearer share multiply bearer share price average month october december prior start performance cycle chf bearer share include annual expense allowance chf payment tax consulting service chf chf additionally employer contribution ahvivalv chf pay form compensation detidua base pay chf r diggelmann hippe g keller oday c wilbur na ayyoubi retire corporate executive committee march total na applicable base pay include prorate remuneration period march december member corporate executive committee detidua base pay member corporate executive committeeroche remuneration report remuneration report roche bonus chf subject approval total aggregate bonus corporate executive committee annual general meeting r diggelmann hippe g keller oday c wilbur na ayyoubi retire corporate executive committee march total na applicable prorate remuneration period march december detidua bonuse member corporate dr severin schwan member stocksettle stock appreciation right ssar chf executive committee corporate executive committee receive ssar ssar remuneration committee board director bonus cash payment determined corporate executive committee april dr severin schwan receive r diggelmann member bonuse base performance bonus form roche share block hippe agree objective total aggregate year bonus payment april g keller bonus bring forward oday bind vote annual general meeting c wilbur na ayyoubi retire corporate executive committee march total na applicable grant ssar grant value chf ssar price chf expiry date stocksettle stock appreciation right fair value ssar calculate ssar member corporate grant date trinomial model american executive committee option trinomial model effective method ssar show ssar table valuation american option consider entitle holder benefit financially possibility exercise option time prior increase value roche nonvoting equity maturity call american option compare security ne grant date european option allow exercise exercise date strike price ssar maturity date term multiyear plan closing price roche ne grant date ssar vest year number ssar strike price expiry date grant date vest ssar exercise grant value ssar show convert ne seven year grant ssar table number ssar date unexercised ssar lapse compensation calculate time issue enter value table page detidua restrict stock unit member award allocate individually remuneration corporate executive committee committee discretion vest restricted stock unit rsusright receive recipient year result nonvoting equity security threeyear vest nonvoting equity security remain block period plus value adjustment year equivalent sum dividend pay vest period attributable number non rsus remuneration component voting equity security individual award corporate executive committee replace grantedwere introduce new awarding correspond psp remuneration component partially replace ssar variable longterm incentive programme value ssar awards reduce corporate executive committee comprise psp award balance award form rsus rsu ssar approximately restrict stock unit rsus number value chf number value chf r diggelmann hippe corporate g keller executive committee oday replace award c wilbur correspond psp na na ayyoubi retire corporate executive committee march total na applicable calculation value consideration reduction value additional block period year reduce market value calculation value consideration reduction value additional block period year reduce market value calculation value number rsus multiply grant value chf ne closing price grant date march rsu information trinomial model american option refer boyle phelim p lattice framework option price state variable journal financial quantitative analysis volume issue mar rochecomtrinomialmodelpdf strike price table ssar detidua performance share plan psp senior management participate performance member corporate executive committee share plan start psp award remuneration component reserve corporate executive psp consist overlap threeyear committee enlarge corporate executive performance cycle new cycle begin committee previous year member year cycle progressroche remuneration report remuneration report roche psp psp security bearer share individual performance share plan psp psp close december award grant require roche target ne award psp security perform well fair value grant fair value grant december target ne peer set event investment bearer share bearer share award psp december roche security underperform average return bearer share bearer share price average price average targeted ne award historical deliver peer company few ne psp performance bearer share award month october months october december december prior fair value prior fair value provision plan number bearer share reserve plan target number start target number target number start target number bearer share performance cycle bearer share bearer share performance cycle bearer share nonvoting equity security nes bearer share member corporate executive committee psp psp psp psp psp psp reserve participant cycle show table number value chf value chf number value chf value chf number security actually award depend board director decide actual level r diggelmann extent investment roche ne bearer share cash equivalent award hippe security share ne outperform average psp cycle ga keller return investment security issue peer close financial year respectively oday set peer company comparison base aim psp provide incentive c wilbur na na na security market price dividend yield ie participant achieve longterm value growth ayyoubi total shareholder return tsr reduce total effect shortterm market fluctuation security price end psp cycle base na applicable average month october threemonth average distribute dividend calculation value nonvoting equity securitiesshare consideration reduction value block period year reduce market december prior start performance cycle totalling chf billion chf billion value retire corporate executive committee march month october december chf billion chf billion end cycle accord term plan participant receive originally target ne roche security perform well average peer set board director elect increase time rsus corporate nes bearer shares award maximum award executive committee replace award double originallevel reserve target number correspond psp longterm incentive nes bearer share accord psp plan plus program corporate executive committee value adjustment equivalent comprise psp ssar award approximately sum dividend pay vest period attributable number nonvoting equity detidua indirect benefit member roche connect voluntary stock purchase plan corporate executive committee offer employee opportunity buy roche employer contribution social nonvoting equity security ne security scheme pension plan groupwide equal annual salary discount employee stock purchase plan roche connect ne purchase plan subject respect member corporate executive hold period year switzerland committee show indirect benefit employer contribution table addition member corporate executive employer contribution show table committee receive annual expense allowance member payment foreign tax obligation tax consulting service show table footnote roche remuneration report remuneration report roche indirect benefit employer contribution chf pension payment pension payment fund annual taxtax fund annual taxtax mgb expense roche consulting mgb expense roche consulting insurance allowance connect service insurance allowance connect service r diggelmann hippe g keller oday c wilbur na na na na ayyoubi total na applicable include employer contribution social security beneficial part r etire corporate executive committee march mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit detidua remuneration loan member total remuneration pay member corporate executive committee corporate executive committee base contractual obligation roche pay calendar year member individual member corporate executive corporate executive committee receive committee children school cost remuneration include bonus total totalling chf chf chf chf exclude additional employer contribution pay ahviv aforementione additional payment include alv totalling chf chf total remuneration member form compensation corporate executive committee additional remuneration loan credit grant mention payment pay current member corporate executive committee member corporate executive committee maximum regular period notice member executive remuneration subject approval corporate executive committee month annual general meeting changeofcontrol clause employment contract submission executive total aggregate bonus bind vote annual remuneration member general meeting corporate executive committee board director propose award member pension total chf corporate executive committee bonus chf pay corporate dr severin schwan form roche share executive committee member block year member corporate executive committee cash payment totalling chf respect financial year chf exclude legally require employer contribution ahvivalv submit propose total ordinary annual general meeting agm binding vote detidua detidua detidua detidua retrospective approval member executive committee total aggregate bonus chf proposal agm agm agm aggregate aggregate aggregate financial year financial year financial year total aggregate proposal approval approve agm exclude legally require employer contribution ahvivalv submission executive total future aggregate incentive ssar calculate grant value remuneration bind shareholder vote consider reduction value block board director propose period applicable psp calculate time ordinary agm approve remuneration reservation nonvoting equity security share corporate executive committee totalling take account maximal potential chf exclude legally require double consider reduction value employer contribution ahvivalv block period contribution pension benefit exclude bonus period end exclude legally require employer contribution ordinary agm ahviv alv contribution expense payment foreign tax obligation tax consulting executive total future aggregate service roche connect remuneration compose base pay longterm prospective approval member executive committee total future aggregate remuneration chf proposal agm agm agm aggregate aggregate aggregate period period period agm agm agm agm agm agm total aggregate proposal approval approve agm exclude legally require employer contribution ahvivalv exclude bonus reconciliation report remuneration exclude bonus period end shareholder prospectively approve ordinary agm remuneration member corporate executive committee comparison ordinary agm ordinary ordinary agm approve remuneration agm remuneration amount chf corporate executive committee totalling exclude legally require employer contribution chf exclude legally require ahvivalv exclude bonus psp employer contribution ahvivalv assumption maximum valueroche remuneration report remuneration report roche prospectively approve total remuneration member executive committee comparison total share nonvoting equity security nes remuneration chf december december total remuneration total remuneration total remuneration close relative close relative period period period share ne security holding share ne security holding agm agm agm agm agm agm number number numbertype number number numbertype maximum total remuneration approve agm corporate executive committee total remuneration calculation end period schwan approve limit calculation end period yes yes r diggelmann additional pay new member hippe corporate executive committee approval ga keller share share agm approved total oday c wilbur na na na exclude legally require employer contribution ahvivalv exclude bonus award ne psp cycle originally include calculation maximum possible award ayyoubi na na na total remuneration period agm agm reduce chf total share share na applicable retired corporate executive committee march clawback accord regulation psp programme addition applicable statutory provision originally target award ne share roche longterm incentive plan include option shall lapse compensation notice ssar partially reclaim distribute compensation termination employment give reason result special circumstance clawback redundancy disability retirement number ssar hold december employee voluntarily serve notice guideline security holding corporate executive committee termination employment ssar rsus board director decide schwan unvested date termination employment ceo roche group cec member r diggelmann lapse immediately compensation acquire share andor nes equivalent annual hippe base salary ceo roche group annual g keller termination employment result base salary respectively end retain oday seriousmisconduct ssar rsus grant holding long serve cec wilbur outstanding vest unvested shall lapse exception cristina wilbur join total immediately compensation accord corporate executive committee ssar plan rule misconduct fulfil requirement end price chf participant include inter alia members corporate executive committee market price ne activity lead disciplinary action fulfil requirement december chf repeat willful failure perform duty expiry date reasonably assign roche security holding grant value ssar chf violation law public regulation december december commission crime respectively member cec persons trinomial model american gross negligence willful misconduct closely associate hold security show option employment table share nonvoting equity security v alue accord engage conduct bring disgrace disrepute ne ssar restrict stock unit rsus correspond annual report roche andor subsidiary violation roche directive guideline relate business conduct type security value acquire ceo roche group share andor nes annual base salary member corporate executive committee share andor nes annual base salary roche remuneration report statutory auditor report roche restrict stock unit rsus number rsus hold december corporate executive general meeting roche holding ltd basel committee schwan r diggelmann corporate audit accompany remuneration audit involve perform procedure obtain hippe executive committee report roche holding ltd year end audit evidence disclosure replace award g keller december audit limited remuneration report regard compensation correspond psp oday information accord article loan credit accordance article wilbur ordinance excessive compensation stock ordinance procedure select depend exchange list company ordinance contain auditor judgement include assessment total section mark blue line include risk material misstatement remuneration grant value rsu chf chf respective footnote page report fraud error audit ne closing price grant date ne average market price remuneration report include evaluate reasonableness method march day period prior grant date apply value component remuneration march assess overall presentation responsibility board director remuneration report chf ne average market price board director responsible day period prior grant date preparation overall fair presentation believe audit evidence obtain october remuneration report accordance swiss law sufficient appropriate provide basis ordinance board director opinion responsible designing remuneration system define individual remuneration package opinion opinion remuneration report auditor responsibility year end december roche holding ltd responsibility express opinion complie swiss law article accompany remuneration report conduct ordinance audit accordance swiss auditing standard standard require comply ethical requirement plan perform audit obtain reasonable assurance remuneration report comply swiss law article ordinance kpmg ag ian starkey marc ziegler license audit expert license audit expert auditor charge basel january kpmg ag viaduktstrasse po box ch basel kpmg ag subsidiary kpmg holding ag member kpmg network independent firm affiliate kpmg international cooperative kpmg international swiss legal entity right reserve roche independent assurance report independent assurance report roche perform assurance engagement obtain limited assurance inspection documentation analysis relevant identify sustainability information policy principle inspect relevant documentation sample basis limited assurance engagement isae revise include roche group sustainability policy management substantially scope reasonable assurance reporting structure documentation independent assurance report engagement relation risk assessment procedure inspect principle roche materiality process include understand internal control provide definition development adherence procedure perform response assess risk gris environmental social economic reporting roche sustainability report consequently nature timing extent procedure requirement address soundness identification gather sufficient appropriate evidence deliberately process determination impact stakeholder peer limited relative reasonable assurance engagement competition review integration relevant regulatory corporate governance sustainability committee roche group internal sustainability report assurance obtain limited assurance requirement integration key organisational value roche holding ag basel guideline base responsible care health safety engagement reasonable assurance engagement objective report prioritisation material aspect environmental protection report guideline publish inspect integration sustainability risk engage perform assurance procedure european chemical industry council cefic procedure select depend assurance opportunity group risk management process provide limited assurance aspect sustainability report guideline g publish practitioner judgement adherence internal guideline sustainability report roche hold ag basel global reporting initiative gri assessment process data consolidation consolidated subsidiary roche include annual roche group internal corporate reporting manual independence quality control review management ofand sustainability reporting report report version sustainability report guidanceeconomic comply independence ethical process contribution people key figure performance requirement code ethic professional accountant assess consolidation process datum roche group level scope subject matter roche materiality determination process corporate issue international ethic standard board limit assurance engagement focus follow level base sustainability report guideline g accountant found fundamental principle conduct work datum outline datum information disclose sustainability reporting publish global reporting initiative gri integrity objectivity professional competence care subject matter define believe evidence roche year end december define guideline people contribution confidentiality professional behaviour obtain sufficient appropriate provide basis management reporting process respect key figure sustainability risk opportunitie assurance conclusion sustainability report material aspect internally gather collate aggregated firm apply international standard quality control preparation safety security health environmental accordingly maintain comprehensive system quality conclusion protection people key figure relate inherent limitation control include document policy procedure base work perform describe report control environment relation datum aggregation accuracy completeness sustainability indicator compliance ethical requirement professional standard identify roche sustainability report come key figure subject inherent limitation give nature method applicable legal regulatory requirement attention cause believe material respect materiality determination process roche group level determine calculate estimate datum roche group internal sustainability report guideline according requirement gri g guideline assurance report read connection summary work perform base gri g sustainability reporting guideline disclose page report roche internal guideline definition procedure assurance procedure include cefic guideline apply design sustainability risk opportunity report sustainability performance follow work roche materiality determination process corporate determination process base roche corporatelevel evaluation application roche group guideline level disclose adhere principle guide activity disclose paragraph risk roche responsibility review application roche group internal factor eg soundness stakeholder determination peer review management report roche corporate governance sustainability committee corporate sustainability contribution guideline relevance regulatory environment integration key people key figure disclose page report responsible subject matter criterion site visit management inquiry organisational value objective define gri g key figure include greenhouse gas emission selection preparation presentation select visit select site roche pharmaceuticals design sustainability risk opportunitie scope scope result business travel information accordance criterion responsibility diagnostic division usa germany japan vietnam determination process corporate level disclose compress air liquid nitrogen waste generate include design implementation maintenance relate indonesia selection base quantitative function design operation table graph page internal control relevant reporting process free qualitative criterion internal reporting process collect aggregate report material misstatement fraud error interview personnel responsible internal sustainability people datum function design provide consolidated data information roche group report datum collection site visit appropriate basis disclosure level relation contribution breakdown disclose responsibility roche group level determine understand internal reporting process collect aggregate page report responsibility form independent opinion base application roche internal sustainability guideline contribution datum function design provide limited assurance procedure come assessment key figure appropriate basis disclosure carry work datum report prior attention indicate identify sustainability perform test sample basis evidence support sustainability information mention subject matter reporting period perform work respect information select contain report state select contribution people key figure ie roche disclose sustainability report roche projection target material respect accordance report criterion accident rate energy consumption greenhouse gas emission annual report state accordance relate energy consumption halogenate hydrocarbon report criterion criterion plan perform procedure accordance water waste contribution healthcare institution patient management reporting process respect international standard assurance engagement organisation public policy body philanthropic zurich january sustainability report key figure prepare isae revise assurance engagement audits organisation headcountfte datum training hour pricewaterhousecoopers ag roche base internal policy procedure set review historical financial information standard concern completeness accuracy adequacy consistency forth follow require comply ethical requirement plan christophe bourgoin bettina buomberger roche imprint imprint roche publish cautionary statement forwardlooke statement earning share growth key date fhoffmannla roche ltd statement profit forecast interpret group communication annual report contain certain forwardlooke mean roche earning earning share basel switzerland statement forwardlooke statement subsequent period necessarily annual general meeting tel identify word believe expect match exceed historical publish earning march wwwrochecom anticipate project intends seek earning share roche estimate future similar expression firstquarter sale orderdownload publication discussion thing strategy goal trademark mention enjoy legal protection april internet rochecompublication plan intention factor cause actual email baselwarehouseservicesrochecom result differ materially future link thirdparty page provide convenience halfyear result fax reflect forwardlooke statement contain express opinion content july annual report price thirdparty page expressly disclaim medium relation product initiative competitor legislative liability thirdparty information use month sale tel regulatory development economic condition october email rochemediarelationsrochecom delay inability obtain regulatory approval roche annual report publish german bring product market fluctuation english investor relation currency exchange rate general financial market tel condition uncertainty discovery reporting consist actual annual report email investorrelationsrochecom development marketing new product new finance report contain annual use exist product include limitation financial statement consolidate financial corporate sustainability committee negative result clinical trial research project statement regard content management tel unexpected effect pipeline market report article incorporation consist email corporatesustainabilityrochecom product increase government pricing pressure aforementione report exception interruption production loss inability remuneration report obtain adequate protection intellectual property right litigation loss key executive print nonchlorine bleach fsccertified paper employee adverse publicity news coverage believe urgent deliver medical solution right noweven develop innovation future passionate transform patient live courageous decision action believe good business mean well world come work day commit scientific rigour unassailable ethic access medical innovation today build well tomorrow proud work function company world rochethe picture submit roche employeesfhoffmannla roche ltd basel switzerland trademark legally protect wwwrochecom roche annual report believe urgent deliver medical solution right noweven develop innovation future passionate transform patient live courageous decision action believe good business mean well world come work day commit scientific rigour unassailable ethic access medical innovation today build well tomorrow proud work function company world roche